var title_f22_47_23280="Simple local reaction";
var content_f22_47_23280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uncomplicated local reaction to Hymenoptera sting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Uncomplicated local reactions from the sting of Hymenoptera insects usually consist of erythema and an area of painful swelling 1 to 2 cm in diameter surrounding the puncture site from the stinger. These reactions typically subside within a few hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Theodore Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23280=[""].join("\n");
var outline_f22_47_23280=null;
var title_f22_47_23281="Proximal PA interrupt I";
var content_f22_47_23281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal interruption of the right pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a small right lung with a diminutive right descending pulmonary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23281=[""].join("\n");
var outline_f22_47_23281=null;
var title_f22_47_23282="Special management LUTS";
var content_f22_47_23282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Specialized management of persistent, bothersome LUTS after basic management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 778px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OAB: overactive bladder; BOO: bladder outlet obstruction; MIST: minimally invasive surgical treatment; Rx: treatment.",
"     <br>",
"      * PSA &lt;1.5 ng.",
"      <br>",
"       &bull; PSA &gt;1.5 ng.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Abrams, P, Chapple, C, Khoury, S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181:1779. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23282=[""].join("\n");
var outline_f22_47_23282=null;
var title_f22_47_23283="Fluorometholone: Pediatric drug information";
var content_f22_47_23283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorometholone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=see_link\">",
"    see \"Fluorometholone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/55/25460?source=see_link\">",
"    see \"Fluorometholone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;;",
"     </li>",
"     <li>",
"      PMS-Fluorometholone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=see_link\">",
"      see \"Fluorometholone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;2 years and Adults: Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: May be applied every 4 hours in severe cases or 1-3 times/day in mild to moderate cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Drops: Instill 1-2 drops into conjunctival sac every hour during day, every 2 hours at night until favorable response is obtained, then use 1 drop every 4 hours; in mild or moderate inflammation: 1-2 drops into conjunctival sac 2-4 times/day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML&reg;: 0.1% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as acetate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flarex&reg;: 0.1% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as base [drops]: 0.1% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML Forte&reg;: 0.25% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML&reg;: 0.1% (5 mL, 10 mL, 15 mL [DSC]) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Suspension (as base)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Avoid contact of medication tube or bottle tip with skin or eye; suspension: Shake well before use; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects; the preservative (benzalkonium chloride) may be absorbed by soft contact lenses; wait at least 15 minutes after administration of suspension before inserting soft contact lenses",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inflammatory conditions of the eye, including keratitis, iritis, cyclitis, and conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3197884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flarex [U.S., Canada, and multiple international markets] may be confused with Fluarix brand name for influenza virus vaccine (inactivated) [U.S. and multiple international markets] and Fluorex brand name for fluoride [France]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F172563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, burning, cataract formation, delayed wound healing, glaucoma, glaucoma with optic nerve damage, intraocular pressure increased, irritation, secondary ocular infection (bacterial, fungal, viral), stinging, visual acuity and field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, systemic hypercorticoidism (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Effects reported with other corticosteroids: Anterior uveitis, bleb formation increased, conjunctival hyperemia, conjunctivitis, corneal ulcers, keratitis, loss of accommodation, mydriasis, perforation of the globe, ptosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorometholone, other corticosteroids, or any component; herpes simplex keratitis, fungal diseases of ocular structures, mycobacterial infections of the eye, and most viral diseases of cornea and conjunctiva",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in glaucoma, increased intraocular pressure, or other ocular damage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following use of ophthalmic fluorometholone. The extent of systemic absorption following topical application of the ophthalmic drops is not known.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure (if used &ge;10 days)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Into aqueous humor with slight systemic absorption",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/55/25460?source=see_link\">",
"      see \"Fluorometholone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause blurring of vision; do not discontinue without consulting physician; notify physician if improvement does not occur after 2 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13313 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23283=[""].join("\n");
var outline_f22_47_23283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172523\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172524\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052905\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052900\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3197884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172563\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052899\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052898\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299353\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172517\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052904\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052897\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052910\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052903\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13313|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=related_link\">",
"      Fluorometholone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/55/25460?source=related_link\">",
"      Fluorometholone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23284="Trolamine: Patient drug information";
var content_f22_47_23284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trolamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/58/1955?source=see_link\">",
"     see \"Trolamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aspercreme&reg; [OTC];",
"     </li>",
"     <li>",
"      Flex-Power [OTC];",
"     </li>",
"     <li>",
"      Mobisyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Myoflex&reg; [OTC];",
"     </li>",
"     <li>",
"      Sportscreme&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antiphlogistine Rub A-535 No Odour;",
"     </li>",
"     <li>",
"      Myoflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703093",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trolamine, salicylate, aspirin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11896 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23284=[""].join("\n");
var outline_f22_47_23284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230991\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012537\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012536\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012541\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012542\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012544\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012539\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012540\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012545\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012546\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/58/1955?source=related_link\">",
"      Trolamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23285="Severe esophagitis";
var content_f22_47_23285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Severe esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of severe reflux esophagitis in a patient who presented with upper gastrointestinal bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23285=[""].join("\n");
var outline_f22_47_23285=null;
var title_f22_47_23286="Sevoflurane: Drug information";
var content_f22_47_23286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sevoflurane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/14/3300?source=see_link\">",
"    see \"Sevoflurane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sojourn&trade;;",
"     </li>",
"     <li>",
"      Ultane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sevorane&reg; AF;",
"     </li>",
"     <li>",
"      Sojourn Sevoflurane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic, Inhalation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     Inhalation: Minimum alveolar concentration (MAC), the concentration that abolishes movement in response to a noxious stimulus (surgical incision) in 50% of patients, is 2.6% (25 years of age). Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3%; the concentration at which amnesia and loss of awareness occur is 0.6%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     MAC values for surgical levels of anesthesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     25 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in oxygen: 2.6%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in 65% N",
"     <sub>",
"      2",
"     </sub>",
"     0/35% oxygen: 1.4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     40 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in oxygen: 2.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in 65% N",
"     <sub>",
"      2",
"     </sub>",
"     0/35% oxygen: 1.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     60 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in oxygen: 1.7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in 65% N",
"     <sub>",
"      2",
"     </sub>",
"     0/35% oxygen: 0.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     80 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in oxygen: 1.4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in 65% N",
"     <sub>",
"      2",
"     </sub>",
"     0/35% oxygen: 0.7%",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     Inhalation: Minimum alveolar concentration (MAC), the concentration that abolishes movement in response to a noxious stimulus (surgical incision) in 50% of patients, is 2.6% (25 years of age). Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3%; the concentration at which amnesia and loss of awareness occur is 0.6%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     MAC values for surgical levels of anesthesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     0 to 1 month old full-term neonates: Sevoflurane in oxygen: 3.3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1 to &lt;6 months: Sevoflurane in oxygen: 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     6 months to &lt;3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in oxygen: 2.8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Sevoflurane in 60% N",
"     <sub>",
"      2",
"     </sub>",
"     0/40% oxygen: 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     3-12 years: Sevoflurane in oxygen: 2.5%",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. MAC is reduced in the elderly (50% reduction by age 80).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, for inhalation: 100% (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sojourn&trade;: 100% (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultane&reg;: 100% (250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Via sevoflurane-specific calibrated vaporizers; use cautiously in low-flow or closed-circuit systems since sevoflurane is unstable and potentially toxic breakdown products have been liberated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction and maintenance of general anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7717184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraoperative cardio-, hepatic-, and neuroprotection (ischemic preconditioning)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ultane&reg; may be confused with Ultram&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (4% to 11%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (7% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (25%), vomiting (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (5%), tachycardia (2% to 6%), hypertension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (9%), dizziness (4%), fever (1%), headache (1%), hypothermia (1%),  emergence delirium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Salivation increased (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Airway obstruction (8%), laryngospasm (2% to 8%), breath-holding (2% to 5%), apnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Shivering (6%), movement (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acidosis, albuminuria, alkaline phosphatase increased,  allergic reactions, ALT increased, AST increased, amblyopia, anaphylactic/anaphylactoid reaction, arrhythmia, atrial arrhythmia, atrial fibrillation, bigeminy, bilirubinemia, bronchospasm, BUN increased, chest discomfort, complete AV block, confusion, conjunctivitis, creatinine increased, creatine phosphokinase increased, crying, dyspnea, facial swelling, fluorosis, glucose increased (transient), glycosuria, hemorrhage, hepatic dysfunction, hepatic failure, hepatic necrosis, hepatitis, hiccup, hyperglycemia, hypersensitivity (rare), hyperkalemia (pediatric patients, postoperative), hypertonia, hyper-/hypoventilation, hypophosphatemia, hypoxia, insomnia, inverted T wave, jaundice, leukocytosis, LDH increased, liver enzymes increased (transient), malignant hyperthermia, myoglobinuria, nervousness, oliguria, pain, pharyngitis, pruritus, rash, second-degree AV block, seizure (rare), sputum increased, ST depression, stridor, supraventricular extrasystoles, syncope, taste perversion, thrombocytopenia, urinary retention, urticaria, ventricular extrasystoles, weakness, wheezing, WBC increased (transient), xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Previous hypersensitivity to sevoflurane, other halogenated anesthetics, or any component of the formulation; known or suspected susceptibility to malignant hyperthermia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agitation/delirium: Monitor for emergence agitation or delirium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis: Postoperative hepatitis or hepatic dysfunction with or without jaundice has rarely been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Use of other inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia; concomitant use of succinylcholine was associated with many of the reported cases, but not all. Risk of hyperkalemia is increased in pediatric patients with underlying neuromuscular disease (eg, Duchenne muscular dystrophy). Other abnormalities may include elevation in CPK and myoglobinuria. Monitor closely for arrhythmias. Aggressively identify and treat hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Sevoflurane produces a dose-dependent reduction in blood pressure and may occur more rapidly compared to other inhaled anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: May dilate the cerebral vasculature and may, in certain conditions, increase intracranial pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignant hyperthermia: May trigger malignant hyperthermia; use is contraindicated in patients susceptible to malignant hyperthermia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Isolated cases of QT prolongation and ones in association with torsade de pointes (rare, but some fatal) have been reported with sevoflurane use; use caution when administering to patients at risk of QT prolongation (eg, concurrent use of class Ia and III antiarrhythmic drugs, elderly patients, congenital QT prolongation) (Han, 2010; Kang, 2006; Nakao, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Causes dose-dependent respiratory depression and blunted ventilatory response to hypoxia and hypercapnia. Hypoxic pulmonary vasoconstriction is blunted which may lead to increased pulmonary shunt.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety with severe impairment has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (ie, creatinine &gt;1.5 mg/dL); safety with severe impairment has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk for seizures; seizures have been reported in children and young adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Desiccated absorbents: Reaction of sevoflurane with CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbents that become desiccated within circle breathing equipment can lead to formation of formaldehyde (causing respiratory irritation) and carbon monoxide; maintain fresh absorbent as per manufacturer guidelines regardless of state of colorimetric indicator. An exothermic reaction of sevoflurane with desiccated CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbents has been reported to generate extreme heat, smoke and/or fire within breathing circuit. This reaction also leads to formation of a fluorinated byproduct, compound A, which has been reported to cause nephrotoxicity (eg, proteinuria, glycosuria) in human and animal studies. Compound A-induced renal toxicity is dose- and exposure time-dependent; minimize exposure risk by not exceeding 2 MAC hours and fresh flow rates &lt;2 L/minute (low fresh gas flow rates maximize rebreathing of the anesthetic). Steps that might reduce the risk of these events include: Replace CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbent if it has not been used for an extended period of time, shut off anesthesia machine at the end of clinical use or after any case when a subsequent extended period of nonuse is expected, turn off all vaporizers when not in use, verify the integrity of new CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbents prior to use, monitor the temperature of the CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbent canisters, and monitor the correlation between sevoflurane vaporizer setting and the inspired concentration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F220860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (minor), CYP2E1 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine.  Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F220823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to rapid washout, sevoflurane levels in breast milk have no clinical importance 24 hours after anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, temperature, heart rate and rhythm, oxygen saturation, end-tidal CO",
"     <sub>",
"      2",
"     </sub>",
"     and end-tidal sevoflurane concentrations should be monitored prior to and throughout anesthesia; temperature of CO",
"     <sub>",
"      2",
"     </sub>",
"     absorbent canister",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F220824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sefether (TH);",
"     </li>",
"     <li>",
"      Sevo (PH);",
"     </li>",
"     <li>",
"      Sevofran (KP);",
"     </li>",
"     <li>",
"      Sevofrane (CL, JP);",
"     </li>",
"     <li>",
"      Sevoran (RU);",
"     </li>",
"     <li>",
"      Sevorane (AR, AT, AU, BG, BO, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GR, GT, HK, HN, HU, ID, IE, IL, IT, KP, LU, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PY, SE, SG, SV, TH, TR, UY, VE);",
"     </li>",
"     <li>",
"      Sojourn (ID, IL, KP, TH);",
"     </li>",
"     <li>",
"      Ultane (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F864323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhaled anesthetics alter activity of neuronal ion channels particularly the fast synaptic neurotransmitter receptors (nicotinic acetylcholine, GABA, and glutamate receptors). Limited effects on sympathetic stimulation including cardiovascular system. Seroflurane does not cause respiratory irritation or circulatory stimulation. May depress myocardial contractility, decrease blood pressure through a decrease in systemic vascular resistance and decrease sympathetic nervous activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sevoflurane has a low blood/gas partition coefficient and therefore is associated with a rapid onset of anesthesia and recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Onset of action: Time to induction: Within 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Emergence time: Depends on blood concentration when sevoflurane is discontinued. The rate of change of anesthetic concentration in the lung is rapid with sevoflurane because of its low blood gas solubility (0.63). The 90% decrement time (time required for anesthetic concentration in vessel-rich tissues to decrease by 90%) for sevoflurane is short when the duration of anesthesia is &lt;2 hours but increases dramatically as the duration of administration is lengthened.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 3% to 5% hepatic via CYP2E1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Exhaled gases",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Beck-Schimmer B, Breitenstein S, Urech S, et al, &ldquo;A randomized Controlled Trial on Pharmacological Preconditioning in Liver Surgery Using a Volatile Anesthetic,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 2008, 248(6):909-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/19092335/pubmed\" id=\"19092335\" target=\"_blank\">",
"        19092335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bein B, Renner J, Caliebe D, et al, &ldquo;The Effects of Interrupted or Continuous Administration of Sevoflurane on Preconditioning Before Cardio-Pulmonary Bypass in Coronary Artery Surgery: Comparison With Continuous Propofol,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2008, 63(10):1046-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/18627368/pubmed\" id=\"18627368\" target=\"_blank\">",
"        18627368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(21):2110-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/12761368/pubmed\" id=\"12761368\" target=\"_blank\">",
"        12761368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Hert SG, Turani F, Mathur S, et al, &ldquo;Cardioprotection With Volatile Anesthetics: Mechanisms and Clinical Implications,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(6):1584-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/15920178 /pubmed\" id=\"15920178 \" target=\"_blank\">",
"        15920178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doi M and Ikeda K, &ldquo;Airway Irritation Produced by Volatile Anaesthetics During Brief Inhalation: Comparison of Halothane, Enflurane, Isoflurane and Sevoflurane,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1993, 40(2):122-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/8443850/pubmed\" id=\"8443850\" target=\"_blank\">",
"        8443850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eger EI 2nd, &ldquo;Characteristics of Anesthetic Agents Used for Induction and Maintenance of General Anesthesia,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(Suppl 4):3-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frink EJ Jr, Ghantous H, Malan TP, et al, &ldquo;Plasma Inorganic Fluoride With Sevoflurane Anesthesia: Correlation With Indices of Hepatic and Renal Function,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 74(2):231-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/1731542/pubmed\" id=\"1731542\" target=\"_blank\">",
"        1731542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golembiewski J, &ldquo;Considerations in Selecting an Inhaled Anesthetic Agent: Case Studies,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61 (Suppl 4):10-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/14725113/pubmed\" id=\"14725113\" target=\"_blank\">",
"        14725113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Han DW, Park K, Jang SB, et al, &ldquo;Modeling the Effect of Sevoflurane on Corrected QT Prolongation: A Pharmacodynamic Analysis,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2010, 113(4):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/20808206/pubmed\" id=\"20808206\" target=\"_blank\">",
"        20808206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones RM, &ldquo;Desflurane and Sevoflurane: Inhalation Anaesthetics for This Decade?&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1990, 65(4):527-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/2248821/pubmed\" id=\"2248821\" target=\"_blank\">",
"        2248821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kang J, Reynolds WP, Chen X, et al, &ldquo;Mechanisms Underlying the QT interval-prolonging Effects of Sevoflurane and Its Interactions With Other QT-prolonging Drugs,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 104(5):1015-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/16645454/pubmed\" id=\"16645454\" target=\"_blank\">",
"        16645454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katoh T, Suguro Y, Nakajima R, et al, &ldquo;Blood Concentrations of Sevoflurane and Isoflurane on Recovery From Anaesthesia,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1992, 69(3):259-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/1389843/pubmed\" id=\"1389843\" target=\"_blank\">",
"        1389843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakao S, Hatano K, Sumi C, et al, &ldquo;Sevoflurane Causes Greater QTc Interval Prolongation in Elderly Patients Than in Younger Patients,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2010, 110(3):775-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/20185656/pubmed\" id=\"20185656\" target=\"_blank\">",
"        20185656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith I, Ding Y, and White PF, &ldquo;Comparison of Induction, Maintenance, and Recovery Characteristics of Sevoflurane-N20 and Propofol-Sevoflurane-N(2)O With Propofol-Isoflurane-N(2)O Anesthesia,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 74(2):253-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/1731547/pubmed\" id=\"1731547\" target=\"_blank\">",
"        1731547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strum DP and Eger EI 2d, &ldquo;Partition Coefficients for Sevoflurane in Human Blood, Saline, and Olive Oil,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1987, 66(7):654-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/3605675/pubmed\" id=\"3605675\" target=\"_blank\">",
"        3605675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang L, Traystman RJ, and Murphy SJ, &ldquo;Inhalational Anesthetics as Preconditioning Agents in Ischemic Brain,&rdquo;",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2008, 8(1):104-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/17962069/pubmed\" id=\"17962069\" target=\"_blank\">",
"        17962069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yasuda N, Lockhart SH, Eger EI 2nd, et al, &ldquo;Comparison of Kinetics of Sevoflurane and Isoflurane in Humans,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1991, 72(3):316-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/47/23286/abstract-text/1994760/pubmed\" id=\"1994760\" target=\"_blank\">",
"        1994760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9887 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23286=[""].join("\n");
var outline_f22_47_23286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220864\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220836\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220850\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220837\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220816\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220818\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220817\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7717184\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220870\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220862\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220821\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220808\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220860\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220811\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220813\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079770\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220823\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220814\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220824\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220820\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/14/3300?source=related_link\">",
"      Sevoflurane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23287="Genomics and model systems";
var content_f22_47_23287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genomics and model systems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Robert D Blank, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23287/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/47/23287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even a complete knowledge of the entire three billion base pairs that make up the human genome (as provided by the Human Genome Project) is insufficient to understand the genetic basis of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/1\">",
"     1",
"    </a>",
"    ]. The sequence data are far more informative if they can be correlated with functional information. This correlation is most readily accomplished through the use of model organisms. Thus, it is best to consider the topics of genomics and model systems together.",
"   </p>",
"   <p>",
"    This topic summarizes some of the most useful on-line sources of genomic information and analysis, and presents selected examples of the use of model systems to explore the relationship between genetic constitution and function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genome is the full complement of genetic information encoded on a complete, haploid set of chromosomes. The human DNA sequence, as defined by the genome project, represents a composite compiled by studying DNA obtained from many individuals. While this data includes considerable information regarding sequence variation among individuals, inter-individual variation remains incompletely cataloged.",
"   </p>",
"   <p>",
"    Efforts to define variation between individuals and to relate such variation to disease risk remain central tasks for human geneticists.",
"   </p>",
"   <p>",
"    Much of this investigation is focused upon single nucleotide polymorphisms (SNPs), sequence variations which occur roughly once in several hundred bases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high density of SNPs and development of methods to efficiently screen for them allow use of SNPs to identify functional genes. Such genes contribute to a wide array of traits, including susceptibility to polygenic diseases and response to pharmaceutical agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two complementary approaches are being pursued to accomplish the goal of relating gene composition to function, or genotype to phenotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic studies seek to establish associations between genes and traits.",
"     </li>",
"     <li>",
"      Functional studies seek to elucidate the mechanisms by which sequence variation lead to phenotypic differences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Structural and functional conservation of the genome over the course of evolution makes genomics a fruitful approach to studying human physiology and pathology. Genes and their protein products are highly conserved. As an example, approximately 30 percent of human genes have an equivalent in yeast (ie, a homolog). The percentage of homologous genes increases as the evolutionary distance between humans and model organisms decreases. The genome sequence of man's closest ancestor, the chimpanzee, shares the highest degree of sequence conservation with the human genome, with only ~1.2 percent divergence in single nucleotide polymorphism.",
"   </p>",
"   <p>",
"    Another type of evolutionary relationship is evident in the organization of the genome: groups of genes physically clustered together on one chromosome in one organism are more often clustered together in other divergent species (so-called syntenic conservation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENOME-BASED EXPERIMENTAL DESIGNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genome-wide association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genome-wide association study (GWAS) is a gene mapping study that assesses evidence of association between genetic variants and heritable traits across the genome. The performance of GWAS is feasible because of the availability of dense SNP coverage across the human genome and genotyping platforms that allow one million genotypes to be assessed in a single experiment. Typical studies consist of genotyping hundreds of thousands of common SNPs, using DNA microarrays in large case-control populations, with the goal of identifying specific risk alleles that are more prevalent in cases than in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GWAS investigations of at least 50 traits or diseases have been reported. While these studies have succeeded in identifying variants in linkage disequilibrium with clinical disorders, the contributions of the allele-specific effects have been only modest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/10\">",
"     10",
"    </a>",
"    ]. As an example, one study of stature identified three alleles affecting height, but the most powerful of these had an estimated effect size of less than half a centimeter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several databases of GWAS investigations are available. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Online sources of genetic information'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Expression quantitative trait loci (eQTL) analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of gene expression within a tissue can be treated as a series of quantitative traits, analogous to stature. The expression of many genes can be measured simultaneously using microarrays. Either linkage mapping (expression quantitative trait loci mapping, eQTL mapping) or GWAS approaches can be used to map and identify sequence variants that account for differences in the levels of expression of specific genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/12\">",
"     12",
"    </a>",
"    ]. Results from such studies can be used to prioritize variants (ie, SNPs) for possible functional impact on human disease. Variants that confer changes in gene expression are more likely to lead to phenotypic variation at the cellular or clinical level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunoprecipitation techniques (ChIP on Chip, ChiP-Seq)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoprecipitation (IP), commonly used to identify protein-protein interactions, has more recently been used to identify protein-DNA interactions, including genome-wide binding patterns of transcription factors and other DNA-binding elements. Results from these studies can be used to map transcription factor binding sites to each of the genes whose expression they control and to define the functional noncoding regions of the genome sequence. Many such annotations are available through the",
"    <a class=\"external\" href=\"file://genome.ucsc.edu/\">",
"     UCSC Human Genome Browser",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Chromatin immunoprecipitation (ChIP) is performed by immunoprecipitation (IP) of fragmented but unpurified DNA, using a transcription factor or other DNA binding protein as the target of the IP. Following the precipitation, the DNA is purified and assayed. Assays are performed genome-wide through the use of microarrays (\"gene chips,\" hence the term \"ChIP on Chip\") [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/13\">",
"     13",
"    </a>",
"    ]. ChiP-seq is a related methodology, in which the immunoprecipitated DNA is sequenced instead of being hybridized to a microarray. This approach requires access to high-throughput sequencing and supporting bioinformatics resources. The resulting data constitute a map of the antigen DNA binding site. (See",
"    <a class=\"local\" href=\"#H26201243\">",
"     'Deep sequencing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26201243\">",
"    <span class=\"h2\">",
"     Deep sequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical advances in DNA sequencing, assembly of sequencing reads, and statistical analysis of sequence data have dramatically reduced the cost of sequencing. This has enabled &ldquo;deep sequencing&rdquo; or &ldquo;next-generation sequencing&rdquo; projects in which the whole exome (protein-encoding portion of the genome) or the whole genome is sequenced to seek biologically-significant sequence variation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Deep sequencing studies have revealed the contribution of rare variants to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In polygenic disorders, deep sequencing has the potential to account for the &ldquo;missing heritability&rdquo; that is encountered in GWAS designs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXAMPLES OF MODEL SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not comprehensive, a few examples of model systems are presented here to illustrate the use of appropriately chosen model systems to relate genetic and functional data. The goal is to highlight what kind of problem each system is best suited to address, and to show how model organisms can be used to gain insights into human health and disease.",
"   </p>",
"   <p>",
"    Model systems allow investigators to relate raw DNA sequence data with functional information. Models are useful insofar as they offer the technical means to accomplish studies that could not be undertaken in human subjects; model organisms permit a host of functional studies that could never be undertaken in a clinical setting.",
"   </p>",
"   <p>",
"    The value of model systems depends upon establishing a proper balance between the simplification they offer and the extent to which they mirror human physiology. These factors usually are inversely related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prokaryocytes and yeast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokaryotic and yeast models derive much of their value from the ability to investigate large experimental populations in search of rare individuals. This is achieved through use of standardized protocols for selecting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    screening for specific mutations. By selection, only individual organisms possessing a specific metabolic property survive to be examined. Screening employs identification of a specific metabolic property in some organisms that results in an easily scored difference, allowing such organisms to be reliably identified, isolated, and recovered for further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bacteriophage lambda",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacteriophage lambda model has advanced general understanding of transcriptional changes in response to environmental stimuli. Lambda is a temperate phage that can grow in either a lytic or lysogenic life cycle. This is manifested morphologically by production of turbid plaques, in which surviving infected bacteria are present. There are various lambda mutants that produce clear plaques in which survival of infected bacteria is much reduced, or behave aberrantly with regard to superinfection. These properties are understood at a detailed molecular level.",
"   </p>",
"   <p>",
"    Interactions of human transcription factors with their cognate DNA response elements and the resulting modulation of transcription are more complex variations on the themes first defined in prokaryotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Yeast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saccharomyces cerevisiae, a yeast, is one of the most fruitful model systems. Yeast have many properties that make them ideal model organisms: the possibility of targeted gene replacement, growth as both a haploid and a diploid organism, and an array of selection and screening schemes. An example of the application of these features was the recent report of the effects of systematic deletion of over 2000 yeast genes under a variety of growth conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/21\">",
"     21",
"    </a>",
"    ]. A significant insight arising from studies in yeast is the discovery of the sirtuin family of proteins, now recognized as critical determinants of longevity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ease of experimental manipulation in yeast makes this model system particularly useful for performing experiments in which many genotypes are screened for function. As an example, the yeast 2-hybrid system allows a systematic search for interactions among proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/23\">",
"     23",
"    </a>",
"    ]. This strategy was applied in a study in which approximately 1000 interacting protein pairs were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/24\">",
"     24",
"    </a>",
"    ]. Importantly, the method is not restricted to yeast proteins, so that interacting proteins from any species can be studied in yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein-protein interactions are important features of virtually every cellular process. At the most basic level, it is important to recall that protein function depends on each protein assuming its proper conformation during synthesis; misfolded proteins lose function. So-called \"chaperone\" proteins interact with nascent peptides to assist in their correct folding during protein synthesis. While nascent protein-chaperone interactions can be studied individually and in other models, the yeast model system is particularly well-suited to global functional analysis of these interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This experimental strategy has been adapted to seek interactions between proteins from other organisms. As noted above, about one-third of human genes have yeast homologs and understanding of human biology has been greatly advanced by study of these in the more easily manipulated yeast system.",
"   </p>",
"   <p>",
"    Data about yeast are readily available at the Saccharomyces genome database (",
"    <a class=\"external\" href=\"file://www.yeastgenome.org/\">",
"     www.yeastgenome.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nematode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nematode Caenorhabditis elegans is used extensively as a model system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/28-36\">",
"     28-36",
"    </a>",
"    ]. Use in developmental biology derives from the ability to trace the cell lineages of every cell [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. C. elegans is a popular model in neurology, as its complete neural circuitry is known, and in studies of aging, as a number of lifespan mutants have been discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/28-36\">",
"     28-36",
"    </a>",
"    ]. The C. elegans system has also provided important insights regarding the role of molecular chaperones in protecting against neurodegenerative diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. elegans data are available through",
"    <a class=\"external\" href=\"file://www.wormbase.org/\">",
"     WormBase",
"    </a>",
"    and the Sanger Centre's",
"    <a class=\"external\" href=\"file://www.acedb.org/\">",
"     ACeDB system",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fruit fly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fruit fly Drosophila melanogaster, the first organism in which detailed linkage maps were constructed, remains an extremely useful model.",
"   </p>",
"   <p>",
"    It has been particularly informative in studies of how spatial information is established during development. The Wnt signaling pathway occupies a central role in mediating multiple aspects of mammalian development and physiology, and it was first found through its homology to the Drosophila wingless gene. Wnt signaling is critical in establishing the body plan and regulating cell polarity and proliferation, including regulating skeletal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An excellent online resource is",
"    <a class=\"external\" href=\"file://flybase.org/\">",
"     Flybase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Zebrafish",
"    </span>",
"    &nbsp;&mdash;&nbsp;The zebrafish is useful because its embryos develop freely, are transparent, and genetic manipulations can be readily performed. Zebrafish are particularly well-suited to studying environmental factors such as drugs and thermal stress because of their small size, aquatic environment, and poikilothermic metabolism. They are also easily amenable to in vivo RNA interference (RNAi), a molecular technique for targeted silencing of specific genes, allowing a wide variety of developmental features to be studied.",
"   </p>",
"   <p>",
"    As an example, RNAi-mediated suppression of HSP90 (90 kD heat shock protein) across several strains of zebrafish resulted in variable ocular development, with some strains demonstrating severe mutations and others more mild phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/45\">",
"     45",
"    </a>",
"    ]. The issues addressed in this study fully exploit the advantages of zebrafish as a model system.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     Z",
"    </strong>",
"    ebra",
"    <strong>",
"     f",
"    </strong>",
"    ish",
"    <strong>",
"     I",
"    </strong>",
"    nformation",
"    <strong>",
"     N",
"    </strong>",
"    etwork provides further information and additional links [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mouse and rat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice are commonly used to study aspects of mammalian physiology that cannot be modeled in invertebrates or non-mammalian vertebrates. Mice are easy to breed, have been extensively studied genetically, and are readily available. There are hundreds of inbred strains, as well as congenic, recombinant inbred, and recombinant congenic strains. The numerous mice mutants available involve all aspects of physiology. A large series of 8-progenitor recombinant inbred mice, the collaborative cross [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/47\">",
"     47",
"    </a>",
"    ], are in development and will allow GWAS in mice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31544?source=see_link\">",
"     \"Mouse genetics: Breeding strategies and genetic engineering\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mice are also used to study the effects of mutating or complementing specific genes, through the use of transgenic technology. This allows study of the consequences of alterations in candidate genes. With the use of Cre-loxP systems, it is possible to engineer specific mutations and to restrict genetic lesions to specific tissues. Specific \"reporter\" mice are widely used to validate these manipulations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/48\">",
"     48",
"    </a>",
"    ] and to assess the activity of specific pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/49\">",
"     49",
"    </a>",
"    ]. These capabilities are being exploited by the",
"    <a class=\"external\" href=\"file://www.knockoutmouse.org/\">",
"     International Knockout Mouse Consortium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/50\">",
"     50",
"    </a>",
"    ], which seeks to generate floxed knockout alleles for every mouse gene.",
"   </p>",
"   <p>",
"    The Jackson Laboratory's",
"    <a class=\"external\" href=\"file://www.informatics.jax.org/\">",
"     Mouse Genome Informatics site",
"    </a>",
"    provides access to information about genes, mutants, inbred strains, mapping and developmental data, and homology to genes in other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. More limited data are available for the rat at the University of Goteborg's RATMAP site (ratmap.gen.gu.se).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ONLINE SOURCES OF GENETIC INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Center for Biotechnology Information (NCBI), operated by the National Library of Medicine, consists of a series of interconnected databases (the full list is given at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar\">",
"     www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar",
"    </a>",
"    ), and serves as a repository for all publically submitted genomic data. The site includes nucleic acid sequence generated through federally-funded genome projects, genetic sequence variants, results from gene expression profiling studies and genome-wide association studies. The Entrez browser system is one possible entry point (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/Entrez\">",
"     www.ncbi.nlm.nih.gov/Entrez",
"    </a>",
"    ). Many readers are already familiar with this site's medical literature search system, PubMed.",
"   </p>",
"   <p>",
"    An Entrez portal (the genotypes and phenotypes database, dbGaP",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/entrez?Db=gap\">",
"     www.ncbi.nlm.nih.gov/sites/entrez?Db=gap",
"    </a>",
"    ) allows users to search by study or disease. The National Human Genome Research Institute also hosts a database of published GWAS (",
"    <a class=\"external\" href=\"file://www.genome.gov/26525384\">",
"     www.genome.gov/26525384",
"    </a>",
"    ). As well, the Japanese government hosts an English language GWAS database",
"    <span class=\"nowrap\">",
"     (https://gwas.lifesciencedb.jp/cgi-bin/gwasdb/gwas_top.cgi).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clinically oriented genome-based databases are OMIM (Online Mendelian Inheritance in Man) and GeneTests.",
"   </p>",
"   <p>",
"    OMIM is a manually curated compendium of genes and genetic phenotypes, regularly updated by reviewers who cull the published literature. Each entry is a full-text overview, with references hyperlinked to PubMed entries. OMIM's emphasis is the relationship between gen locus, genetic variation, and their phenotypic consequences. OMIM also provides the historical context in which understanding about various genes and diseases has emerged.",
"   </p>",
"   <p>",
"    In contrast, GeneTests is geared towards clinicians needing guidance in management of patients with genetic conditions. The database provides detailed synopses of each genetic condition, including lists of differential diagnoses, guidelines for clinical management, genetic counseling, and genetic testing. Importantly, this site also provides contact information for CLIA-certified laboratories that test for pathogenic mutations in disease genes, and investigators registered as having interest in specific genes or conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Research orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Entrez system also allows users to conduct a variety of analyses. For example, the",
"    <a class=\"external\" href=\"file://blast.ncbi.nlm.nih.gov/Blast.cgi\">",
"     BLAST algorithm",
"    </a>",
"    enables searching of all nucleotide (DNA) or protein databases for sequence homologies to a query sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/53-59\">",
"     53-59",
"    </a>",
"    ]. BLAST reports include all sequence matches and provide metrics of the strength of alignment, confidence scores for the alignment, and graphical depictions of the alignments.",
"   </p>",
"   <p>",
"    While Entrez is extremely flexible and comprehensive, its interface is not as easy to use as that of several other resources that are more graphics-based. Two easily used graphics-based genome browsers are Ensembl (",
"    <a class=\"external\" href=\"file://www.ensembl.org/index.html\">",
"     www.ensembl.org/index.html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/60\">",
"     60",
"    </a>",
"    ] and the",
"    <a class=\"external\" href=\"file://genome.ucsc.edu/\">",
"     UCSC Genome Browser",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/61\">",
"     61",
"    </a>",
"    ]. These browsers provide graphical representation of the genome with sequence annotation of genes, variants, functional elements, and other types of genomic data. Much of the information presented is derived from the NCBI database, and daily cross-references and updates of NCBI, Ensembl and the UCSC browser ensure similar query retrievals regardless of which interface is used for the query.",
"   </p>",
"   <p>",
"    The Weizmann Institute's",
"    <a class=\"external\" href=\"file://www.genecards.org/\">",
"     GeneCards site",
"    </a>",
"    is a well-organized gene-centered database, providing genomic, proteomic, and functional information on all known and predicted human genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23287/abstract/62\">",
"     62",
"    </a>",
"    ]. The included information is primarily geared toward researchers, but includes links to diseases, drugs, and drug candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understanding the genetic basis for human disease involves knowledge both of genome sequences and of gene function. Knowledge of variations in gene sequence is largely dependent on the use of single nucleotide polymorphisms (SNPs) in a variety of study designs. Gene function studies are enabled by the use of model systems. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basic concepts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genome-based experimental designs include genome-wide association studies (GWAS), quantitative analysis of gene expression (eQTL analysis), and studies involving immunoprecipitation techniques. Although GWAS studies have identified multiple variants associated with clinical disorders, the physiologic effect of the GWAS-identified individual variant alleles has been relatively modest. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genome-based experimental designs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple model systems, chosen appropriately for their unique properties, can give insight to the relationship between genetic composition and function within the species. The value of model systems depends upon establishing a proper balance between the simplification they offer and the extent to which they mirror human physiology. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Examples of model systems'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/1\">",
"      Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/2\">",
"      Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/3\">",
"      Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/4\">",
"      Chakravarti A. Population genetics--making sense out of sequence. Nat Genet 1999; 21:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/5\">",
"      Kwok PY, Gu Z. Single nucleotide polymorphism libraries: why and how are we building them? Mol Med Today 1999; 5:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/6\">",
"      Eppig JT, Nadeau JH. Comparative maps: the mammalian jigsaw puzzle. Curr Opin Genet Dev 1995; 5:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/7\">",
"      DeBry RW, Seldin MF. Human/mouse homology relationships. Genomics 1996; 33:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/8\">",
"      Nadeau JH. Maps of linkage and synteny homologies between mouse and man. Trends Genet 1989; 5:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/9\">",
"      Seldin MF. Genome surfing: using internet-based informatic tools toward functional genetic studies in mouse and humans. Methods 1997; 13:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/10\">",
"      Stein CM, Elston RC. Finding genes underlying human disease. Clin Genet 2009; 75:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/11\">",
"      Estrada K, Krawczak M, Schreiber S, et al. A genome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation. Hum Mol Genet 2009; 18:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/12\">",
"      Cookson W, Liang L, Abecasis G, et al. Mapping complex disease traits with global gene expression. Nat Rev Genet 2009; 10:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/13\">",
"      Acevedo LG, Iniguez AL, Holster HL, et al. Genome-scale ChIP-chip analysis using 10,000 human cells. Biotechniques 2007; 43:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/14\">",
"      Ku CS, Naidoo N, Pawitan Y. Revisiting Mendelian disorders through exome sequencing. Hum Genet 2011; 129:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/15\">",
"      Ng PC, Kirkness EF. Whole genome sequencing. Methods Mol Biol 2010; 628:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/16\">",
"      Mestan KK, Ilkhanoff L, Mouli S, Lin S. Genomic sequencing in clinical trials. J Transl Med 2011; 9:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/17\">",
"      Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009; 461:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/18\">",
"      Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 2009; 106:19096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/19\">",
"      1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/20\">",
"      Zaboli G, Ameur A, Igl W, et al. Sequencing of high-complexity DNA pools for identification of nucleotide and structural variants in regions associated with complex traits. Eur J Hum Genet 2012; 20:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/21\">",
"      Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999; 285:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/22\">",
"      Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/23\">",
"      Brent R, Finley RL Jr. Understanding gene and allele function with two-hybrid methods. Annu Rev Genet 1997; 31:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/24\">",
"      Uetz P, Giot L, Cagney G, et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 2000; 403:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/25\">",
"      Parrish JR, Gulyas KD, Finley RL Jr. Yeast two-hybrid contributions to interactome mapping. Curr Opin Biotechnol 2006; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/26\">",
"      Gong Y, Kakihara Y, Krogan N, et al. An atlas of chaperone-protein interactions in Saccharomyces cerevisiae: implications to protein folding pathways in the cell. Mol Syst Biol 2009; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/27\">",
"      Engel SR, Balakrishnan R, Binkley G, et al. Saccharomyces Genome Database provides mutant phenotype data. Nucleic Acids Res 2010; 38:D433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/28\">",
"      Hodgkin J, Horvitz HR, Jasny BR, Kimble JC. Elegans: Sequence to Biology. Science 1998; 282:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/29\">",
"      C. elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 1998; 282:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/30\">",
"      Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998; 282:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/31\">",
"      Pennisi E. Worming secrets from the C. elegans genome. Science 1998; 282:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/32\">",
"      Blaxter M. Caenorhabditis elegans is a nematode. Science 1998; 282:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/33\">",
"      Ruvkun G, Hobert O. The taxonomy of developmental control in Caenorhabditis elegans. Science 1998; 282:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/34\">",
"      Clarke ND, Berg JM. Zinc fingers in Caenorhabditis elegans: finding families and probing pathways. Science 1998; 282:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/35\">",
"      Bloom FE. Staying afloat on the seas of data. Science 1998; 282:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/36\">",
"      Chervitz SA, Aravind L, Sherlock G, et al. Comparison of the complete protein sets of worm and yeast: orthology and divergence. Science 1998; 282:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/37\">",
"      Deppe U, Schierenberg E, Cole T, et al. Cell lineages of the embryo of the nematode Caenorhabditis elegans. Proc Natl Acad Sci U S A 1978; 75:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/38\">",
"      Sulston JE, Schierenberg E, White JG, Thomson JN. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol 1983; 100:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/39\">",
"      Prahlad V, Morimoto RI. Integrating the stress response: lessons for neurodegenerative diseases from C. elegans. Trends Cell Biol 2009; 19:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/40\">",
"      Harris TW, Antoshechkin I, Bieri T, et al. WormBase: a comprehensive resource for nematode research. Nucleic Acids Res 2010; 38:D463.",
"     </a>",
"    </li>",
"    <li>",
"     Durbin, R, Meig, JT. A C. elegans database: Documentation, code and data available from anonymous FTP servers at lirmm.lirmm.fr, cele.mrc-lmb.cam.ac.uk and ncbi.nlm.nih.gov. (1991-2000).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/42\">",
"      Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/43\">",
"      MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/44\">",
"      Tweedie S, Ashburner M, Falls K, et al. FlyBase: enhancing Drosophila Gene Ontology annotations. Nucleic Acids Res 2009; 37:D555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/45\">",
"      Yeyati PL, Bancewicz RM, Maule J, van Heyningen V. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genet 2007; 3:e43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/46\">",
"      Sprague J, Bayraktaroglu L, Clements D, et al. The Zebrafish Information Network: the zebrafish model organism database. Nucleic Acids Res 2006; 34:D581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/47\">",
"      Churchill GA, Airey DC, Allayee H, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004; 36:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/48\">",
"      Mao X, Fujiwara Y, Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A 1999; 96:5037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/49\">",
"      DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/50\">",
"      Ringwald M, Iyer V, Mason JC, et al. The IKMC web portal: a central point of entry to data and resources from the International Knockout Mouse Consortium. Nucleic Acids Res 2011; 39:D849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/51\">",
"      Blake JA, Bult CJ, Kadin JA, et al. The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res 2011; 39:D842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/52\">",
"      Smith CM, Finger JH, Hayamizu TF, et al. The mouse Gene Expression Database (GXD): 2007 update. Nucleic Acids Res 2007; 35:D618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/53\">",
"      Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990; 215:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/54\">",
"      Altschul SF, Madden TL, Sch&auml;ffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/55\">",
"      Gish W, States DJ. Identification of protein coding regions by database similarity search. Nat Genet 1993; 3:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/56\">",
"      Madden TL, Tatusov RL, Zhang J. Applications of network BLAST server. Methods Enzymol 1996; 266:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/57\">",
"      Zhang J, Madden TL. PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation. Genome Res 1997; 7:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/58\">",
"      Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol 2000; 7:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/59\">",
"      Morgulis A, Coulouris G, Raytselis Y, et al. Database indexing for production MegaBLAST searches. Bioinformatics 2008; 24:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/60\">",
"      Hubbard TJ, Aken BL, Beal K, et al. Ensembl 2007. Nucleic Acids Res 2007; 35:D610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23287/abstract/61\">",
"      Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002; 12:996.",
"     </a>",
"    </li>",
"    <li>",
"     Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: Encyclopedia for genes, proteins and diseases., Weizmann Institute of Science, Rehovot, Israel 1997.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2903 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23287=[""].join("\n");
var outline_f22_47_23287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENOME-BASED EXPERIMENTAL DESIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genome-wide association studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Expression quantitative trait loci (eQTL) analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunoprecipitation techniques (ChIP on Chip, ChiP-Seq)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26201243\">",
"      Deep sequencing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXAMPLES OF MODEL SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prokaryocytes and yeast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bacteriophage lambda",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Yeast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nematode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fruit fly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Zebrafish",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mouse and rat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ONLINE SOURCES OF GENETIC INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical orientation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Research orientation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31544?source=related_link\">",
"      Mouse genetics: Breeding strategies and genetic engineering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23288="Chemotherapy and immunotherapy for medullary thyroid cancer";
var content_f22_47_23288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy and immunotherapy for medullary thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Steven I Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23288/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/47/23288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary thyroid cancers (MTCs) are neuroendocrine tumors of thyroid parafollicular cells that do not concentrate iodine. They occur both as sporadic tumors and as components of multiple endocrine neoplasia (MEN) type 2. They secrete calcitonin and carcinoembryonic antigen (CEA), both of which can serve as tumor markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary treatment for MTC is extensive and meticulous surgical resection. There is a limited role for external-beam radiotherapy. Because the neuroendocrine-derived MTC is not responsive to either radioiodine or TSH-suppression, these options are not available for treatment of progressive metastatic MTC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with progressive or symptomatic metastatic disease who cannot be treated by surgery or radiotherapy should be considered candidates for systemic therapy. New approaches based upon application of targeted chemotherapies are emerging as effective interventions for progressive disease, although most remain investigational. Alternatively, treatment with either cytotoxic chemotherapy or biologic response modifiers may provide some benefit for occasional patients who fail or are ineligible for targeted therapies.",
"   </p>",
"   <p>",
"    Current and experimental chemotherapies for advanced medullary thyroid carcinomas will be reviewed here. Chemotherapies for differentiated and anaplastic thyroid carcinomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28345?source=see_link\">",
"     \"Chemotherapy for differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=see_link\">",
"     \"Anaplastic thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYROSINE KINASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other tumors, tyrosine kinases function in MTC to stimulate tumor proliferation, angiogenesis, invasion, and metastasis. Small molecule inhibitors of select tyrosine kinases have been of interest for the treatment of advanced MTC, given the oncogenic role of inherited and somatic mutations in the tyrosine kinase RET, as well as the contributory roles of tyrosine kinases in growth factor receptors such as the vascular endothelial growth factor receptor (VEGFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These drugs partially inhibit multiple kinases at nanomolar concentrations and often affect multiple signaling pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Small molecule tyrosine kinase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    On the basis of a randomized phase III trial that demonstrated significant prolongation of progression-free survival,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    is available in the United States for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Other tyrosine kinase inhibitors (TKIs) remain investigational for the treatment of advanced MTC. In preliminary trials, partial responses are reported in approximately 20 to 50 percent of patients. Although complete responses are rare, TKIs can potentially provide long-term disease stabilization. However, there are no data on the ability of any of these agents to improve survival.",
"   </p>",
"   <p>",
"    For most patients with progressive advanced MTC, we suggest participation in clinical trials of therapies targeting the molecular and cellular pathogenesis of MTC. In patients who are unable to participate in clinical trials, we suggest an oral TKI, rather than a cytotoxic agent. As",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    have both been approved for use in the United States on the basis of randomized phase III trial results, we suggest either drug as an appropriate initial choice of tyrosine kinase inhibitor.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    are alternative options.",
"   </p>",
"   <p>",
"    In the studies described below, the definitions of tumor response are based upon the now-standard Response Evaluation Criteria in Solid Tumors (RECIST), version 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10576313\">",
"    <span class=\"h2\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    (ZD6474) is an oral inhibitor that targets VEGFR, RET, and the epidermal growth factor receptor (EGFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/4\">",
"     4",
"    </a>",
"    ]. In a phase II trial limited to patients with metastatic or unresectable hereditary MTC (either familial MTC or MEN2a), vandetanib, 300 mg daily, was administered to 30 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/5\">",
"     5",
"    </a>",
"    ]. Confirmed partial response was observed in six (20 percent) patients, and another 16 (53 percent) patients had stable disease lasting at least 24 weeks. The most common adverse events that occurred in more than half of patients were diarrhea, rash, fatigue, and nausea.",
"   </p>",
"   <p>",
"    In a trial of lower dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    (100 mg daily) in 19 patients with metastatic or unresectable hereditary MTC, the response rates were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/6\">",
"     6",
"    </a>",
"    ]. Confirmed objective partial responses were reported in three patients (16 percent) and stable disease lasting at least 24 weeks in 10 patients (53 percent). Although the dose was lower, side effects were similar. During the trial, four patients with disease progression while taking the 100 mg dose received post-progression treatment with 300 mg.",
"   </p>",
"   <p>",
"    An international randomized phase III trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    (300 mg daily) was performed in over 300 patients with unresectable locally advanced or metastatic sporadic or hereditary MTC. After a median follow-up of 24 months, progression-free survival was significantly prolonged for patients randomly assigned to vandetanib versus placebo (hazard ratio 0.46, 95% CI 0.31-0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The median progression-free survival had not yet been reached for the vandetanib group but was predicted to be 30.5 months compared with 19.3 months in the placebo group. The objective response rate was significantly higher in the vandetanib group (45 versus 13 percent). No difference has been observed in overall survival between the two treatment arms despite the improvement in progression-free survival, although the final survival analysis will be performed when sufficient number of deaths have occurred. Patients with both progressive and stable disease were eligible for enrollment, and outcomes were similar in the two groups. However, patients with CEA doubling times greater than 24 months were unlikely to benefit from treatment. The presence of a somatic RET M918T mutation predicted an improved progression-free survival.",
"   </p>",
"   <p>",
"    Common side effects occurring in &ge;20 percent of patients included",
"    <span class=\"nowrap\">",
"     diarrhea/colitis,",
"    </span>",
"    rash, dermatitis, nausea, hypertension, headache, fatigue, anorexia, abdominal pain, hypocalcemia, decreased glucose, and increased ALT. Severe adverse effects (occurring in &ge;5 percent) included",
"    <span class=\"nowrap\">",
"     diarrhea/colitis,",
"    </span>",
"    hypertension and hypertensive crisis, QT prolongation, fatigue, and rash. Torsades de pointes and sudden death have been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the results from the phase III trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    is available in the United States (US) through a Risk Evaluation Mitigation Strategy (REMS) program and in Europe where it is monitored by the Commission on Human Medicines and the Medicines and Healthcare products Regulatory Agency, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. In the US, distribution is restricted to prescribers and pharmacies participating in the REMS program. The recommended starting daily dose is 300 mg orally. For patients with moderate (creatinine clearance 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and severe (&lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    renal impairment, the starting dose should be reduced to 200 mg daily. Electrocardiograms (ECGs) and serum potassium, calcium, magnesium, and TSH should be obtained at two to four weeks and 8 to 12 weeks after starting treatment and every three months thereafter. Patients with diarrhea may require more frequent monitoring.",
"   </p>",
"   <p>",
"    An ongoing randomized trial is now evaluating the relative efficacy and tolerability of starting with the lower 100 mg daily dose compared with the approved 300 mg dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H652134\">",
"    <span class=\"h2\">",
"     Cabozantinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     Cabozantinib",
"    </a>",
"    (XL184) is also approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/12\">",
"     12",
"    </a>",
"    ]. Cabozantinib is an oral, small molecule TKI that targets VEGFRs 1 and 2, c-MET, and RET [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/13\">",
"     13",
"    </a>",
"    ]. The inhibitory activity against c-MET, the cognate receptor for the hepatocyte growth factor, may provide additional synergistic benefit in MTC.",
"   </p>",
"   <p>",
"    In a phase I dose-escalation study, 10 of 35 MTC patients (29 percent) achieved a confirmed partial response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/14\">",
"     14",
"    </a>",
"    ]. Stable disease of at least six months duration was observed in 15 of 37 patients with MTC. The overall rate of partial responses and six month progression-free survival was 68 percent. Responses were seen in patients regardless of the RET mutation status of their tumors, indicating that the drug is active in patients without RET activating mutations.",
"   </p>",
"   <p>",
"    In a randomized trial, 330 patients with progressive, metastatic or unresectable locally advanced medullary thyroid cancer were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    (140 mg) or placebo once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. A significant prolongation in progression free survival was observed for cabozantinib treatment compared with placebo (11.2 versus 4.0 months; HR 0.28 [95% CI 0.19-0.40]). Partial responses were observed in 27 versus 0 percent. The most common side effects, occurring in &ge;25 percent of patients, were diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension, and abdominal pain. Although uncommon, clinically significant adverse events included fistula formation and osteonecrosis of the jaw. Significant electrocardiographic abnormalities were not observed.",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    is 140 mg daily, with dose reductions to adjust for tolerability. Although not mandated in its approval, safety monitoring during therapy should include periodic assessment of electrolytes, calcium, and TSH.",
"   </p>",
"   <p>",
"    We prefer that patients with progressive advanced or symptomatic MTC participate in clinical trials of targeted therapies. However, for those patients who are unwilling or unable to participate in clinical trials, we suggest either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    as the initial choice of TKI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    (Nexavar) is an oral, small molecule TKI that targets VEGFR 2 and 3 and most mutant forms of RET [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/16\">",
"     16",
"    </a>",
"    ]. In a pilot study, five patients with metastatic MTC were treated with sorafenib, starting at 400 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/17\">",
"     17",
"    </a>",
"    ]. After six months of treatment, responses were described in two (including one complete response) and symptomatic improvement was seen in all, but most patients required a dose reduction due to side effects.",
"   </p>",
"   <p>",
"    In addition, preliminary results from a larger (n = 16), open-label phase II study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in patients with metastatic MTC showed a partial response in one patient with sporadic MTC and a median progression-free survival of nearly 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/18\">",
"     18",
"    </a>",
"    ]. Partial response (n = 3) or durable stable disease (n = 3) was also reported in six of eight MTC patients participating in a phase I study of combination sorafenib and tipifarnib [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is approved in the US for treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. It could be considered for use in selected patients with advanced MTC who are unable to participate in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    (Sutent) is an oral, small molecule TKI that targets all three VEGFRs and RET [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/20\">",
"     20",
"    </a>",
"    ]. Preliminary results in patients with MTC include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prolonged partial response was described in one patient with MTC treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , 50 mg daily for 28 days followed by 14 days of no treatment per cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an open-label phase II trial in patients with progressive refractory thyroid cancer (n = 7 with MTC) with a median follow-up of 15.5 months, three MTC patients had a complete or partial response, and disease stabilization occurred in two [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interim analysis from a second open-label phase II trial reported partial responses or stable disease for greater than 12 weeks in three of eight MTC patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is approved in the US for treatment of advanced renal cell carcinoma and also for refractory gastrointestinal stromal tumors. It could be considered for use in selected thyroid cancer patients with metastatic disease warranting therapy outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    (Votrient) is an orally administered potent small molecule TKI that targets all VEGFR subtypes, but has no significant inhibitory activity against RET [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/24\">",
"     24",
"    </a>",
"    ]. Therefore, its actions are expected to be primarily anti-angiogenic in MTC. In a preliminary report on 14 patients with rapidly progressing MTC treated in a phase II trial, one patient (7 percent) experienced a partial response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/25\">",
"     25",
"    </a>",
"    ]. Eight (57 percent) were alive without progression, two (14 percent) were alive with progression, and four (29 percent) had died. The study has continued on to a second stage, enrolling up to 28 patients. The efficacy of pazopanib to induce objective responses in the absence of significant anti-RET activity suggests that RET may not be as important a target for therapy as the VEGF receptor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is approved in the US for the treatment of advanced renal cell carcinoma. In the absence of more extensive data in medullary thyroid cancer patients, we do not recommend using the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3778567\">",
"    <span class=\"h2\">",
"     Side effects and their management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects that are common to all of the VEGF-targeted TKIs include hypertension, renal toxicity, bleeding, myelosuppression, arterial thromboembolism, cardiotoxicity, thyroid dysfunction (typically hypothyroidism), cutaneous toxicity including hand-foot skin reaction, delayed wound healing, hepatotoxicity, and muscle wasting. These side effects and their management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Investigational tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other TKIs have been studied in clinical trials during the past several years, but these drugs remain investigational at this time and are not available for routine clinical use. In general, the results of these studies are consistent with the findings described above, supporting the concept that antiangiogenic TKIs are useful treatments for advanced metastatic MTC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Motesanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motesanib is a highly selective TKI that targets all three VEGFRs, platelet-derived growth factor receptor (PDGFR), and RET. In a phase II study, 91 patients with advanced or progressive symptomatic MTC were treated with motesanib (125 mg orally daily) for up to 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/26\">",
"     26",
"    </a>",
"    ]. Partial response was confirmed in only two patients and 44 (48 percent) had stable disease for at least 24 weeks. The most common adverse events were diarrhea and fatigue (41 percent), hypertension, anorexia, and nausea (each occurring in approximately 27 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CYTOTOXIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with progressive metastatic MTC, treatment with traditional cytotoxic agents provides limited benefit. Partial responses are reported in approximately 10 to 20 percent of patients, but long-term responses are uncommon. The availability of tyrosine kinase inhibitors that can stabilize progressive metastatic disease is changing the standard approach to treating these patients, further limiting the role of cytotoxic agents. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Tyrosine kinase inhibitors'",
"    </a>",
"    above.) Thus, we do not consider traditional cytotoxic agents a first-line therapy for patients with persistent or recurrent MTC. We reserve these agents for patients who are unable to participate in clinical trials or cannot tolerate or fail kinase inhibitors.",
"   </p>",
"   <p>",
"    Most regimens for patients with MTC combine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    with other agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , without significant advantage of one combination compared with another [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/27\">",
"     27",
"    </a>",
"    ]. In one widely cited report, the combination of cyclophosphamide (750",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    vincristine (1.4",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    and dacarbazine (600",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    daily for two days in each cycle) every three weeks was administered to seven patients with metastatic MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/28\">",
"     28",
"    </a>",
"    ]. Two patients experienced &gt;50 percent shrinkage in tumor dimensions lasting more than one year, and two others had stable disease.",
"   </p>",
"   <p>",
"    A more complex regimen (repeating cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    on day one, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    daily for five consecutive days, followed four weeks later with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , 400",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , 200",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    daily for five consecutive days) was given to 20 patients with progressing distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/29\">",
"     29",
"    </a>",
"    ]. Three patients (15 percent) had partial responses lasting more than 18 months, and 10 (50 percent) were stable for at least eight months. Toxicities of dacarbazine include neutropenia, thrombocytopenia, nausea, vomiting, and hepatotoxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    (60 to 75",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    every three weeks, or 15",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly) is approved by the US Food and Drug Administration for the treatment of all histologies of metastatic thyroid carcinoma including MTC, but fewer than 30 percent of patients have an objective response, none are complete, and the duration is generally short [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    is administered as a continuous intravenous infusion for 48 to 72 hours to minimize the risk of cardiac toxicity. Common adverse events can include granulocytopenia with accompanying infections, nausea, vomiting, and alopecia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy of thyroid cancer holds some promise, but as yet has had little clinical application. One approach is to induce host immunity to the tumor by administering tumor-derived vaccines or inoculations of tumor-cell transfectants expressing specific cytokines. Another is to administer monoclonal antibodies coupled to radioisotopes to deliver radiotherapy. These therapies have been tried more often for patients with MTC than for other types of thyroid cancer. However, they remain investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tumor vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel approach to targeted immunotherapy is the use of tumor vaccines. Dendritic cells, which are derived from bone marrow antigen-presenting cells, are capable of presenting tumor-associated antigens, thereby generating cytotoxic T-cells targeting tumor cells.",
"   </p>",
"   <p>",
"    In preliminary studies in patients with metastatic MTC, treatment with stimulated dendritic cells was promising, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, dendritic cells were obtained from each of seven patients and stimulated in the presence of both calcitonin and CEA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/32\">",
"       32",
"      </a>",
"      ]. Following periodic intracutaneous injections of the stimulated dendritic cells, one patient experienced a partial response, including complete regression of hepatic metastases, which was associated with a 70 percent reduction in serum tumor markers. Two other patients had mixed responses.",
"     </li>",
"     <li>",
"      In another study, dendritic cells were stimulated using lysates of each individual patient's surgically resected primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/33\">",
"       33",
"      </a>",
"      ]. Three of 10 patients had partial responses, including one with complete resolution of radiographic evidence of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Toxicities in both of these trials were minor, including low-grade fever and asymptomatic transient autoantibody development. Further small studies are underway, refining the procedures to enhance the potency of the dendritic cell vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Radioimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression of CEA on MTC cells led to the exploitation of radiolabeled anti-CEA monoclonal antibodies for radioimmunotherapy. In the initial trials, antitumor effects were noted using",
"    <span class=\"nowrap\">",
"     anti-CEA/anti-diethylenetriamine",
"    </span>",
"    pentaacetic acid (DTPA)-indium recombinant bispecific antibody (BsMAb), followed four days later by a 131I-labeled bivalent hapten [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/36\">",
"     36",
"    </a>",
"    ]. In a subsequent nonrandomized trial in patients with progressive metastatic MTC (defined as a calcitonin doubling time less than two years), median overall survival after administration of this therapy was 110 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/37\">",
"     37",
"    </a>",
"    ]. This compared favorably with a contemporaneous untreated cohort's median survival of only 60 months.",
"   </p>",
"   <p>",
"    Significant toxicities included grade 4 neutropenia and thrombocytopenia, lasting up to three weeks, and one patient (who had received previous radiotherapies) developed myelodysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiolabeled octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase II trial in 31 patients with progressive metastatic MTC, treatment with radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N'''-tetraacetic acid [(90)Y-DOTA]-Tyr(3)-octreotide (TOC) resulted in decreases in calcitonin levels in nine patients (29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/38\">",
"     38",
"    </a>",
"    ]. Responders had a significantly longer median survival (109 months from time of diagnosis compared with 80 months in nonresponders). Hematologic and renal toxicities occurred in four and seven patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of tyrosine kinase inhibitors that can stabilize progressive metastatic disease is changing the standard approach to treating metastatic MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Although it may take many months before radiographic response becomes evident, targeting angiogenesis (and specifically VEGFR signaling pathways) has produced the most impressive clinical responses to date in MTC. Complete responses are rare, but kinase inhibitors can potentially provide long-term disease stabilization and delay progression in selected patients. However, no study has yet reported these agents' effects to improve survival. In addition, eventual progression despite antiangiogenic VEGFR blockade has occurred during the treatment of other malignancies, suggesting emergence of alternate pathways to promote tumor growth and metastasis (including FGFR, C-MET, and angiopoietins) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These newer \"targeted therapies\" have significant toxicities and, therefore, it is important to limit the use of systemic treatments to patients at significant risk for morbidity or mortality due to progressive metastatic disease. Patients treated with systemic agents should have a baseline performance status sufficiently functional to tolerate these interventions, such as being ambulatory at least 50 percent of the day (ECOG performance status 2 or better).",
"   </p>",
"   <p>",
"    In the absence of sufficient clinical trial data comparing both efficacy and safety of any individual drug or combination, the following treatment strategy is based upon clinical experience and data from open label studies. Our approach is consistent with the American Thyroid Association Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23288/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with asymptomatic metastatic tumors generally less than 1 to 2 cm in diameter, growing in diameter less than 20 percent per year, we suggest observation, treating problems like diarrhea with symptomatic support. Known sites of metastatic disease should be imaged by CT or MRI every 6 to 12 months, and potential new sites of disease should be imaged every 12 to 24 months.",
"     </li>",
"     <li>",
"      For patients with metastatic tumors at least 1 to 2 cm in diameter, growing by at least 20 percent per year, or for patients with symptoms related to multiple metastatic foci that cannot be alleviated with surgery or external beam radiotherapy, we prefer to administer systemic treatment as part of a clinical trial. (Active clinical trials can be identified at",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=thyroid+cancer&amp;recr=Open\">",
"       www.clinicaltrials.gov",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients who cannot participate in a clinical trial, we suggest an oral TK inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"       cabozantinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       Sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      are alternative options. For patients who cannot tolerate or who fail multiple TK inhibitors, we suggest cytotoxic chemotherapy, of which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      -based regimens such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      -dacarbazine may be preferable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall goal of developing new treatments is to extend the duration of life without unduly harming the quality of that life. Presently, no novel treatment has been demonstrated to improve survival for thyroid cancer patients. Toxicities of many of these new therapies, although probably less life-threatening than cytotoxic chemotherapies, are common and can be dose-limiting, and clinicians must be familiar with recognizing and managing the side effects if they intend to use these agents. Finally, the low rate of partial response, the absence of complete responses, and emergence of resistance in all of the various monotherapy trials identify the need to develop either more effective single agents or to identify rational combinations of therapeutic targets (including cytotoxic chemotherapies) that have synergistic effectiveness without enhanced cross-toxicities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medullary thyroid cancers (MTCs) are neuroendocrine tumors of thyroid parafollicular cells that do not concentrate iodine. The primary treatment for MTC is extensive and meticulous surgical resection. There is a limited role for external-beam radiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"       \"Medullary thyroid cancer: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with asymptomatic metastatic tumors generally less than 1 to 2 cm in diameter, growing in diameter less than 20 percent per year, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      giving systemic therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Such patients should be monitored for disease progression. Known sites of metastatic disease should be imaged by CT or MRI every 6 to 12 months, and potential new sites of disease should be imaged every 12 to 24 months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic tumors at least 1 to 2 cm in diameter, growing by at least 20 percent per year, or for patients with symptoms related to multiple metastatic foci that cannot be alleviated with surgery or external beam radiotherapy, we prefer to administer systemic treatment as part of a clinical trial. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic tumors at least 1 to 2 cm in diameter, growing by at least 20 percent per year, or for patients with symptoms related to multiple metastatic foci who cannot participate in a clinical trial, we suggest an oral tyrosine kinase inhibitor (TKI), rather than traditional cytotoxic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For initial TKI therapy, we suggest cabozantinib or vandetanib rather than sorafenib or sunitinib (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Cytotoxic chemotherapy, of which dacarbazine-based regimens such as cyclophosphamide-vincristine-dacarbazine are preferable, is an alternative option for patients who cannot tolerate or who fail multiple TKIs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tyrosine kinase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Cytotoxic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/1\">",
"      Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/2\">",
"      Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/3\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/4\">",
"      Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/5\">",
"      Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/6\">",
"      Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.",
"     </a>",
"    </li>",
"    <li>",
"     file://www1.astrazeneca-us.com/pi/vandetanib.pdf (Accessed on April 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/8\">",
"      Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002315/WC500123533.pdf (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     file://www.medicines.org.uk/EMC/medicine/26040/SPC/Caprelsa+100+mg+%26+300+mg+film+coated+tablets/ (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA approves Cometriq to treat rare type of thyroid cancer. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm (Accessed on December 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/13\">",
"      Cui, JJ. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat 2007; 17:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/14\">",
"      Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29:2660.",
"     </a>",
"    </li>",
"    <li>",
"     Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012; 30 (suppl):5508. file://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5508 (Accessed on January 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/16\">",
"      Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/17\">",
"      Kober, F, Hermann, M, Handler, A, Krotla, G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2007; 25:14065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/18\">",
"      Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/19\">",
"      Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009; 15:7061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/20\">",
"      Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/21\">",
"      Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008; 148:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/22\">",
"      Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16:5260.",
"     </a>",
"    </li>",
"    <li>",
"     Ravaud, A, de la Fouchardi&egrave;re, C, Courbon, F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 2008; 26;6058.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/24\">",
"      Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/25\">",
"      Bible, KC, Smallridge, RC, Maples, WJ, et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol (Meeting Abstracts) 2009; 27:3521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/26\">",
"      Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27:3794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/27\">",
"      Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007; 36:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/28\">",
"      Wu LT, Averbuch SD, Ball DW, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994; 73:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/29\">",
"      Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs &agrave; Calcitonine (GETC). Br J Cancer 2000; 83:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/30\">",
"      Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/31\">",
"      Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose adriamycin. Br J Clin Pract 1990; 44:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/32\">",
"      Schott M, Seissler J, Lettmann M, et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001; 86:4965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/33\">",
"      Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004; 10:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/34\">",
"      Papewalis C, Wuttke M, Jacobs B, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/35\">",
"      Bachleitner-Hofmann T, Friedl J, Hassler M, et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009; 21:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/36\">",
"      Kraeber-Bod&eacute;r&eacute; F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/37\">",
"      Chatal JF, Campion L, Kraeber-Bod&eacute;r&eacute; F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/38\">",
"      Iten F, M&uuml;ller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007; 13:6696.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/40\">",
"      American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/41\">",
"      Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/42\">",
"      Tsimberidou AM, Vaklavas C, Wen S, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009; 94:4423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23288/abstract/43\">",
"      Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2188 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23288=[""].join("\n");
var outline_f22_47_23288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10576313\">",
"      Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H652134\">",
"      Cabozantinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3778567\">",
"      Side effects and their management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Investigational tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Motesanib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CYTOTOXIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INVESTIGATIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tumor vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Radioimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiolabeled octreotide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28345?source=related_link\">",
"      Chemotherapy for differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23289="Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease";
var content_f22_47_23289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23289/contributors\">",
"     David H Spach, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23289/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/47/23289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cat scratch disease (CSD) is an infectious disease characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, clinical features, and diagnosis of CSD will be reviewed here. The treatment of CSD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37925?source=see_link\">",
"     \"Treatment of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical descriptions of cat scratch disease (CSD) existed for more than 50 years, the first convincing evidence of an infectious cause of CSD came in 1983 when investigators at the Armed Forces Institute of Pathology, using a Warthin-Starry stain, demonstrated small, pleomorphic organisms in the lymph nodes of 29 of 34 patients with CSD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Afipia felis first was believed to be the cause of CSD after investigators isolated this organism from patients with CSD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, current serologic and culture data provide convincing evidence that Bartonella henselae is the etiologic agent in most cases of CSD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In humans and cats, two main B. henselae genotypic groups have been identified based on molecular analysis: the Houston-1 serotype and Marseille serotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/9\">",
"     9",
"    </a>",
"    ]. One report also described a case of CSD caused by B. clarridgeiae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, scattered, uncommon cases of CSD may result from A. felis, B. clarridgeiae, and perhaps other, as yet unidentified, fastidious organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among HIV-infected persons (and less commonly other immunocompromised individuals), B. henselae can cause bacillary angiomatosis (BA), peliosis hepatis, and splenitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8182?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"    </a>",
"    .) Rare reports have also documented BA among immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of CSD remains poorly understood. Disease manifestations result from either local infection, such as lymphadenopathy, or from bloodborne disseminated infection, such as occurs with neuroretinitis or visceral organ involvement. Cats serve as the natural reservoir for B. henselae and the organism causes intraerythrocytic bacteremia that can persist for a year or longer in some cats [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/13\">",
"     13",
"    </a>",
"    ]. Following inoculation of B. henselae into humans, the organism typically causes a local infection that manifests as regional lymphadenopathy. Within the human host, B. henselae invades endothelial cells causing an acute inflammatory reaction associated with activation of a proinflammatory cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/14\">",
"     14",
"    </a>",
"    ]. It remains unknown why some patients have infection that remains localized whereas others develop disseminated disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available data suggest that cat scratch disease (CSD) can result from a cat scratch or bite, as well as from a flea bite. Cats are the main reservoir for B. henselae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/15\">",
"     15",
"    </a>",
"    ]. Rare cases of CSD occur after exposure to a dog, presumably resulting from flea bites.",
"   </p>",
"   <p>",
"    In a prospective, population-based study performed in Connecticut during the years 1992 and 1993, the overall annual incidence of CSD was 3.7 per 100,000 persons; the highest age-specific attack rate occurred in those under the age of 10, 9.3 per 100,000 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/16\">",
"     16",
"    </a>",
"    ]. In another study, CSD was identified in 61 of 454 patients (13 percent) with primary head and neck masses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSD appears to occur in a broad geographic distribution in North America. Cases have a seasonal distribution with a peak in fall and early winter. CSD may rarely occur in family clusters with more than one child in the family presenting simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/18\">",
"     18",
"    </a>",
"    ]. Epidemiologic studies from the United States, Europe, Israel, Australia, and Japan, have identified that CSD has a worldwide distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSD generally occurs in young immunocompetent individuals and infrequently causes serious illness. In one study using a United States national database, the incidence of CSD was approximately 9 to 10 cases per 100,000 persons per year (22,000 cases per year); most cases occurred in persons less than 21 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/20\">",
"     20",
"    </a>",
"    ]. Although most commonly a disease of children and young adults, a surveillance study conducted in Israel found that 52 of 846 (6 percent) immunocompetent patients with CSD were &ge;60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSD can also occur in immunocompromised patients. Systemic CSD has been described in patients who have undergone solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/22-24\">",
"     22-24",
"    </a>",
"    ] and in a patient being treated with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple lines of evidence have directly linked CSD to exposure to cats, especially young cats and cats with fleas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/1,7,26\">",
"     1,7,26",
"    </a>",
"    ]. The cat flea, Ctenocephalides felis, plays a critical role in the horizontal cat-to-cat transmission of B. henselae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/27\">",
"     27",
"    </a>",
"    ]. In one study of 205 cats in northern California, B. henselae bacteremia was documented in 56 and 34 percent of cats less than one year and at least one year of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/28\">",
"     28",
"    </a>",
"    ]. Moreover, 90 and 77 percent of cats less than one and one year or older, respectively, had positive B. henselae serology.",
"   </p>",
"   <p>",
"    Fleas have also been implicated in the transmission of CSD. In one study of 60 CSD patients and 56 age-matched controls, exposure to kittens (odds ratio (OR) 15), a scratch or bite by a kitten (OR 27), and having a kitten with fleas (OR 29) were more common among cases than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/7\">",
"     7",
"    </a>",
"    ]. In a study of B. henselae antibodies in catteries, flea infestation was the risk factor most associated with high seroprevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cat scratch disease (CSD) presents in 85 to 90 percent of children as a localized cutaneous and lymph node disorder near the site of organism inoculation. In some individuals, the organisms disseminate and infect the liver, spleen, eye, or central nervous system. Patients with localized disease generally have a self-limited illness, whereas those with disseminated disease can have life-threatening complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSD typically begins with a cutaneous lesion at the site of inoculation, the so-called primary inoculation lesion. This lesion usually develops three to ten days after the introduction of the organism into the skin and generally evolves through vesicular, erythematous, and papular phases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef78770 \" href=\"UTD.htm?7/60/8128\">",
"     picture 1",
"    </a>",
"    ). Less commonly the primary inoculation lesion can be pustular or nodular. One report described a patient who developed a paronychia (painful periungual inflammation) caused by B. henselae as a manifestation of an inoculation site lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/32\">",
"     32",
"    </a>",
"    ]. The primary inoculation lesion typically persists for one to three weeks (range several days to several months).",
"   </p>",
"   <p>",
"    Careful examination of the interdigital spaces, skin creases, and scalp increases the chance of finding the primary inoculation lesion. Inoculation sites other than the skin occur in about five to ten percent of cases and include the eye (nonsuppurative conjunctivitis, ocular granuloma) and mucous membranes (oral ulcer) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/30\">",
"     30",
"    </a>",
"    ]. The inoculation lesions usually cause minimal symptoms and heal without scarring.",
"   </p>",
"   <p>",
"    Other uncommon cutaneous manifestations of CSD include a transient macular and papular eruption, erythema multiforme, erythema nodosum, and thrombocytopenic purpura [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional lymphadenopathy is the hallmark of CSD. Enlarged lymph nodes appear proximal to the inoculation site, about two weeks (range, seven to 60 days) after the organism is inoculated into the skin (",
"    <a class=\"graphic graphic_picture graphicRef52407 \" href=\"UTD.htm?33/63/34814\">",
"     picture 2",
"    </a>",
"    ). The nodes are almost always tender, often have erythema of the overlying skin, and occasionally suppurate (10 to 15 percent). Node size typically ranges from one to five cm, but may enlarge to eight to 10 cm.",
"   </p>",
"   <p>",
"    The location of the lymphadenopathy depends on the site of the inoculation; the most common locations are the axillary, epitrochlear, cervical, supraclavicular, and submandibular lymph nodes. In one study, solitary lymphadenopathy occurred in approximately 85 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/31\">",
"     31",
"    </a>",
"    ]. Less commonly, patients presented with several enlarged nodes in the same anatomic region. In another study, regional adenopathy (single or multiple nodes) occurred in approximately two-thirds of cases, with the remaining one-third of patients having enlarged nodes in several anatomic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/30\">",
"     30",
"    </a>",
"    ]. Generalized lymphadenopathy is rare. Lymphadenopathy associated with CSD usually resolves in one to four months, but reports have described persistence of enlarged nodes for one to three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Visceral organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described patients with CSD who had involvement of the liver, spleen, or both. Visceral organ involvement is one of the more common manifestations of CSD in children after lymphadenopathy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Patients may have persistent fever of unknown origin, abdominal pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/36\">",
"     36",
"    </a>",
"    ]. About half of children have hepatomegaly or splenomegaly; the liver may be tender to palpation. Many of the patients with visceral involvement have no accompanying peripheral adenopathy. In one review, 100 of 832 patients (12 percent) with CSD had splenomegaly, but these were not patients in whom granulomatous splenitis was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An abdominal CT scan will typically show scattered, multiple defects in the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spleen that if biopsied, would show necrotizing granulomas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56489 \" href=\"UTD.htm?14/42/15010\">",
"     image 1",
"    </a>",
"    ). Biopsies are now rarely performed because the clinical and imaging findings are so characteristic. These are manifested as hypoechoic areas on ultrasound.",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) is typically elevated and liver function tests may be mildly abnormal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fever of unknown origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. henselae infection should be considered in the initial evaluation of fever of unknown origin and prolonged fever in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. A prospective analysis of 146 children with fever of unknown origin and prolonged fever found that B. henselae was the third most common infectious disease diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/40\">",
"     40",
"    </a>",
"    ]. Although some of these patients presented with signs and symptoms consistent with typical CSD or hepatosplenic involvement, three of seven patients with confirmed B. henselae infection presented with fever of unknown origin and no clinical or radiographic manifestations of typical or hepatosplenic CSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiologies of fever of unknown origin in children\", section on 'Cat scratch disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular manifestations of CSD include Parinaud's oculoglandular syndrome, neuroretinitis, papillitis, optic neuritis, and focal retinochoroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Parinaud's oculoglandular syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parinaud's oculoglandular syndrome is an atypical form of CSD, reported in from two to eight percent of patients with CSD, and can include conjunctivitis, conjunctival granuloma, and adjacent preauricular lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The inoculation of the organism occurs via a cat bite or lick near (or in) the eye, as well as by self-inoculation from another site. Serious ocular, orbital, or retinal complications almost never develop as a result of local extension of Parinaud's oculoglandular syndrome. One report described isolation of B. henselae from a conjunctival scraping in a patient with Parinaud's oculoglandular syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neuroretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among all patients with CSD, about one to two percent develop neuroretinitis. Neuroretinitis is a syndrome of acute visual loss from optic nerve edema associated with macular exudates; B. henselae is believed to be one of the most common infectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/45\">",
"     45",
"    </a>",
"    ]. The frequency of CSD as a cause of neuroretinitis is illustrated by a serologic study of patients with neuroretinitis that found 9 of 14 (64 percent) had either elevated IgM or IgG B. henselae titers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with neuroretinitis typically present with fever, malaise, and unilateral blurred vision [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/47\">",
"     47",
"    </a>",
"    ]. On examination, patients usually have unilateral involvement, with decreased visual acuity, often associated with an afferent pupillary defect. Retinal findings may include hemorrhages, cotton wool spots, multiple discrete lesions in the deep retina, and stellate macular exudates (known as a \"macular star\") (",
"    <a class=\"graphic graphic_picture graphicRef69294 \" href=\"UTD.htm?31/62/32736\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/47\">",
"     47",
"    </a>",
"    ]. However, patients with B. henselae-induced neuroretinitis may not develop a macular star until one to four weeks after initial presentation, and some patients never develop a macular star [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/41\">",
"     41",
"    </a>",
"    ]. The macular exudates in CSD can persist for months before resolving, and some patients have residual defects that include optic disk pallor, diminished contrast sensitivity, and altered color vision [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/41\">",
"     41",
"    </a>",
"    ]. Most patients with neuroretinitis, however, appear to have a good long-term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/41,47\">",
"     41,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case report described a 10-year-old girl with CSD who developed a macular hole 12 days after presentation with neuroretinitis in association with a posterior vitreous detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of neurologic manifestations are described in patients with CSD, including [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Encephalopathy (most common)",
"     </li>",
"     <li>",
"      Transverse myelitis",
"     </li>",
"     <li>",
"      Radiculitis",
"     </li>",
"     <li>",
"      Cerebellar ataxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with encephalopathy typically develop abrupt confusion and disorientation, which may progress to coma, approximately one to six weeks after initially presenting with adenopathy. Most of these patients will develop seizures and some develop focal neurologic findings such as hemiparesis as a result of cerebral vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with CSD encephalopathy, laboratory findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normal computed tomography (CT) scan of the brain &mdash; most patients",
"     </li>",
"     <li>",
"      Mild mononuclear pleocytosis in the cerebrospinal fluid (CSF) (usually &lt;50",
"      <span class=\"nowrap\">",
"       cell/mm3)",
"      </span>",
"      &mdash; 20 to 30 percent",
"     </li>",
"     <li>",
"      An abnormal electroencephalogram &mdash; most patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although patients typically recover from CSD encephalopathy within several weeks, some will have residual neurologic defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Musculoskeletal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe and often disabling musculoskeletal manifestations may occur in patients with CSD. In a surveillance study of 913 patients with CSD in Israel, 96 (10.5 percent) had musculoskeletal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/52\">",
"     52",
"    </a>",
"    ]. These included myalgia (6 percent), arthritis or arthralgia (5.5 percent), and less commonly tendinitis, osteomyelitis, and neuralgia.",
"   </p>",
"   <p>",
"    The knee, ankle, wrist, hand, and elbow joints were the most frequently affected. Although joint complaints resolved in the majority of patients, five patients developed chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Multivariate analysis identified the following characteristics significantly associated with arthropathy (arthritis or arthralgia):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female sex (relative risk [RR], 1.89; 95% CI 1.01-3.52)",
"     </li>",
"     <li>",
"      Age greater than 20 years (RR, 11.0; 95% CI 4.3-28.2)",
"     </li>",
"     <li>",
"      Erythema nodosum (RR, 4.07; 95% CI 1.38-12.02)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of bone infection associated with CSD, published prior to the above study, found 47 cases reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/54\">",
"     54",
"    </a>",
"    ]. The median age was 9 years. Bone pain and fever were the predominant clinical manifestations and the most commonly affected sites were the vertebral column and pelvic girdle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other atypical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scattered reports have documented rare manifestations of CSD, including hypercalcemia, deep neck space infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/55\">",
"     55",
"    </a>",
"    ], culture-negative endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/56\">",
"     56",
"    </a>",
"    ], scalp eschar with neck lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/57\">",
"     57",
"    </a>",
"    ], pneumonia, pleural effusion, septic shock, and thrombocytopenic purpura. The hypercalcemia is associated with overproduction of calcitriol, the most active form of vitamin D, and appears to be related to granuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients with CSD are more likely to present with atypical features. In the surveillance study in Israel mentioned above, clinical data for patients with CSD aged &ge;60 years (elderly group) were compared with patients with CSD aged &lt;60 years (nonelderly group) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/21\">",
"     21",
"    </a>",
"    ]. The elderly group was more likely to have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General malaise (71 compared to 51 percent in the nonelderly)",
"     </li>",
"     <li>",
"      Atypical CSD (33 compared to 14 percent in the nonelderly); including endocarditis (odds ratio [OR], 61.6; 95% CI, 12.4-305.1), encephalitis (OR, 6.3; 95% CI, 1.2-33.3), and fever of unknown origin (OR, 7.3; 95% CI, 2.2-24.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphadenitis, the hallmark of typical CSD, was less common in the elderly group (77 compared to 94 percent in the nonelderly). For these reasons, the time from onset of symptoms to diagnosis of CSD in elderly persons was more commonly delayed for &gt;6 weeks (30 compared to 13 percent in the nonelderly).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cat scratch disease (CSD) primarily includes other infectious and malignant causes of lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/30,59\">",
"     30,59",
"    </a>",
"    ]. The importance of excluding mycobacterial disease and malignancy by analysis of a lymph node biopsy specimen is illustrated by the analysis of 786 lymph node specimens from patients with suspected CSD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/60\">",
"     60",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious agents were identified in 391 of 786 (50 percent) of patients. The most commonly identified infectious agent was B. henselae (245 patients, 31 percent).",
"     </li>",
"     <li>",
"      Mycobacterial infection was diagnosed in 54 patients (7 percent)",
"     </li>",
"     <li>",
"      Malignancy was diagnosed in 47 of 181 patients in whom specimens suitable for histologic analysis were available (26 percent of those analyzed, 6 percent of total).",
"     </li>",
"     <li>",
"      Concurrent disease was diagnosed in 13 patients; CSD and either mycobacterial disease (10 patients) or malignancy (3 patients)",
"     </li>",
"     <li>",
"      No diagnosis was obtained in 350 patients (45 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of tender lymph nodes suggests an infectious cause. The most common infectious causes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial adenitis (caused by Staphylococcus aureus or group A beta-hemolytic streptococci)",
"     </li>",
"     <li>",
"      Lymphadenopathy accompanied by a cutaneous inoculation lesion (caused by atypical mycobacteria, Nocardia species, Francisella tularensis, Erysipelothrix rhusiopathiae, Bacillus anthracis, Yersinia pestis, or Borrelia burgdorferi) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"       \"Evaluation of peripheral lymphadenopathy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H6#H6\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Localized lymphadenopathy'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Viral-associated lymphadenopathy (caused by cytomegalovirus, HIV, or Epstein-Barr virus)",
"     </li>",
"     <li>",
"      Toxoplasmosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"       \"Toxoplasmosis in immunocompetent hosts\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare infectious causes include histoplasmosis and sporotrichosis.",
"   </p>",
"   <p>",
"    Lymphoma is the most common malignancy that can be confused with CSD. In some circumstances, a lymph node biopsy may need to be performed to exclude lymphoma, especially in those patients who have an atypical presentation or who have delayed resolution of systemic symptoms. Other noninfectious causes include congenital and acquired cysts, Kawasaki's disease, Kikuchi's disease, and sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CSD may be suspected from the typical clinical findings, but laboratory evaluation is required to confirm the clinical impression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/15\">",
"     15",
"    </a>",
"    ]. A laboratory diagnosis of CSD is often made on the basis of a positive serologic test (ie, a positive B. henselae antibody titer). However, serologic testing has serious shortcomings. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Serology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It has been suggested that at least three of four of the following criteria be present to establish the diagnosis of CSD in patients with typical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cat or flea contact regardless of the presence of an inoculation site lesion",
"     </li>",
"     <li>",
"      Negative serology for other causes of adenopathy; sterile pus aspirated from a node; a positive Bartonella PCR assay;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver or spleen lesions seen on CT scan",
"     </li>",
"     <li>",
"      Positive serology for B. henselae (enzyme immunoassay [EIA] or indirect fluorescence assay [IFA]) with a titer ratio of &ge;1:64",
"     </li>",
"     <li>",
"      Biopsy showing granulomatous inflammation consistent with CSD or a positive Warthin-Starry silver stain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, some experts suggest that a positive serologic test is generally adequate for diagnosis in patients with typical clinical manifestations of CSD. In patients with atypical findings, a tissue biopsy is often performed to investigate a number of potential causes. When a biopsy is performed, PCR and culture of the tissue should be obtained in addition to routine histopathologic studies. Although isolation of B. henselae by culture provides a definitive diagnosis, B. henselae is difficult to isolate from tissue specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two serologic methods, the indirect fluorescence assay (IFA) and enzyme immunosorbent assay (EIA) have been evaluated for diagnosis. One study found a higher proportion of patients with presumed CSD had an indirect IFA B. henselae IgG titers of &ge;1:64 compared to healthy controls (88 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/6\">",
"     6",
"    </a>",
"    ]. However, four subsequent studies from Europe reported problems with B. henselae IFA tests including poor sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/62,63\">",
"     62,63",
"    </a>",
"    ] and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The reported problems with the B. henselae IFA serology tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant cross-reactivity at the species level between B. henselae and B. quintana, especially for IgG assays",
"     </li>",
"     <li>",
"      Sensitivity of the test does not appear to be optimal, especially with IgG assays",
"     </li>",
"     <li>",
"      Prevalence of positive Bartonella serology in the general population is four to six percent, which creates false positive tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both the IFA and EIA tests have undergone study, commercially available assays use the IFA test. In the United States, three references labs are commonly used for Bartonella serology testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated Regional University Pathologists (Salt Lake City Utah):",
"      <span class=\"nowrap\">",
"       www.aruplab.com/guides/ug/tests/0050108.jsp,",
"      </span>",
"      phone: 800-522-2787",
"     </li>",
"     <li>",
"      Focus Diagnostics (Cypress, California): www.focusdx.com, phone: 714-220-1900 or 800-445-0185",
"     </li>",
"     <li>",
"      Specialty Laboratories, Inc. (Santa Monica, California):",
"      <span class=\"nowrap\">",
"       file://specialtylabs.com;",
"      </span>",
"      phone number for client services: 800-421-4449. This laboratory has very poor correlation with Centers for Disease Control and Prevention (CDC) results for Bartonella serology (Kaplan, SL, Baylor College of Medicine, 2006, personal communication).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, IFA IgG titers &lt;1:64 suggest the patient does not have a current Bartonella infection; a low positive titer may represent past infection. Titers between 1:64 and 1:256 represent possible Bartonella infection; repeat testing in 10 to 14 days is recommended. Titers &gt;1:256 strongly suggest active or recent infection. A positive IgM test strongly suggests acute disease (or very recent infection), but the production of IgM is usually brief. Thus, the serologic diagnosis of acute infection can be elusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. henselae is a fastidious, slow-growing, gram-negative bacterium that requires specific laboratory conditions for optimal growth. Blood culture samples should be collected in pediatric or adult isolator tubes (Wampole, Cranbury, NJ) or in blood tubes containing ethylenediaminetetraacetic acid (EDTA) to increase the probability of isolating B. henselae.",
"   </p>",
"   <p>",
"    Plating samples onto either chocolate agar or heart infusion agar supplemented with five percent rabbit blood enhances isolation of organisms from subcultures. Optimally, the microbiology lab should use fresh agar plates and incubate them in five percent CO2 at 35 to 37&ordm;C for a minimum of 21 days. Even employing optimal techniques, most patients with CSD do not have B. henselae isolated from blood cultures.",
"   </p>",
"   <p>",
"    Isolation of B. henselae from tissue samples remains very difficult, but a successful isolation in HIV-infected patients has been reported by directly plating tissue homogenates onto agar and co-cultivating with a bovine endothelial cell monolayer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of the primary inoculation lesion site reveals acellular areas of necrosis in the dermis. Histiocytes and epithelioid cells surround the areas of necrosis in multiple layers, with the innermost layer often showing a palisading arrangement. A zone of lymphocytes surrounds the histiocytes; multinucleated giant cells are variably present. Although these findings support a diagnosis of CSD, they should not be considered definitive.",
"   </p>",
"   <p>",
"    The histopathologic findings in involved lymph nodes are nonspecific and depend upon the stage of the disease. Lymphoid hyperplasia is present initially, followed by the development of stellate granulomas. The centers are acellular and necrotic; histiocytes and peripheral lymphocytes surround these areas, similar to findings in skin samples. Microabscesses develop and may become confluent at a later stage.",
"   </p>",
"   <p>",
"    Warthin-Starry stain may demonstrate delicate pleomorphic B. henselae bacilli in chains, clumps, or filaments within areas of necrosis of involved lymph nodes and in the primary inoculation site of the skin. Although a positive Warthin-Starry stain does not provide a definitive diagnosis of CSD, it would strongly suggest a diagnosis of CSD if observed in conjunction with compatible clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR based tests for Bartonella have become commercially available. The different PCR tests have utilized amplification of three distinct regions: 16S rRNA, citrase synthase gene (gltA), or htrA gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/15\">",
"     15",
"    </a>",
"    ]. These PCR tests have high specificity and can distinguish among the different Bartonella species, but sensitivity has not been optimal, ranging from 43 to 76 percent.",
"   </p>",
"   <p>",
"    The PCR test on tissue or blood is available commercially through either Focus Technologies or Specialty Laboratories, Inc. A rapid single-step PCR assay for Bartonella that amplifies the 16S-23S rRNA intergenic regions has shown promise [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/67\">",
"     67",
"    </a>",
"    ]. Use of PCR testing of serum samples in patients with cat scratch disease lymphadenitis has low sensitivity (&lt;20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of biopsy may influence whether or not PCR from tissue is positive in CSD. In a study of 61 patients with CSD cited above, PCR was positive in only 10 of the 212 lymph node specimens on which this test was performed; 9 of the 10 positive patients had a duration of illness of less than six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with a compatible clinical presentation and serologic evidence of B. henselae infection (single IgG titer &ge;1:512, four-fold increase in titer between paired serum specimens, or IgG titer between 1:64 and 1:256 accompanied by a positive IgM) were considered to have CSD in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CSD skin test, one of the original four criteria for diagnosis of CSD, is no longer used since other more specific and sensitive diagnostic tools are preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. In addition, the skin test antigen is not widely available, is not standardized, and is not approved by the Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23289/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/40/35457?source=see_link\">",
"       \"Patient information: Cat scratch disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cat scratch disease (CSD) is an infectious disease characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bartonella henselae is the etiologic agent in most cases of CSD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple lines of evidence have directly linked CSD to exposure to cats, especially young cats and cats with fleas. CSD can result from a cat scratch or bite, as well as from a flea bite. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CSD most often (in 85 to 90 percent of children) presents as a localized cutaneous and lymph node disorder near the site of organism inoculation. In some individuals, the organisms disseminate and infect the liver, spleen, eye, bone, or central nervous system. Patients with localized disease generally have a self-limited illness, whereas those with disseminated disease can have life-threatening complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B. henselae infection should be considered in the initial evaluation of fever of unknown origin (FUO) and prolonged fever in children. In one study, CSD was the third most common cause of FUO in children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fever of unknown origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular manifestations of CSD include Parinaud's oculoglandular syndrome, neuroretinitis, papillitis, optic neuritis, and focal retinochoroiditis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ocular manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of CSD primarily includes other infectious and malignant causes of lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CSD is based on typical clinical findings (ie, lymphadenopathy) associated with probable exposure to cats or fleas. Laboratory testing that is supportive of a diagnosis includes a positive B. henselae antibody titer or a positive Warthin Starry stain or PCR analysis of tissue. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of CSD that present with atypical clinical manifestations, the diagnosis relies heavily on a positive serologic test. However, in atypical cases, if a tissue sample is obtained, a definitive laboratory diagnosis should be attempted by either culture or PCR. Although isolation of B. henselae by culture provides a definitive diagnosis, B. henselae is very difficult to isolate from tissue specimens. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/1\">",
"      Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/2\">",
"      Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/3\">",
"      Wear DJ, Margileth AM, Hadfield TL, et al. Cat scratch disease: a bacterial infection. Science 1983; 221:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/4\">",
"      English CK, Wear DJ, Margileth AM, et al. Cat-scratch disease. Isolation and culture of the bacterial agent. JAMA 1988; 259:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/5\">",
"      Brenner DJ, Hollis DG, Moss CW, et al. Proposal of Afipia gen. nov., with Afipia felis sp. nov. (formerly the cat scratch disease bacillus), Afipia clevelandensis sp. nov. (formerly the Cleveland Clinic Foundation strain), Afipia broomeae sp. nov., and three unnamed genospecies. J Clin Microbiol 1991; 29:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/6\">",
"      Regnery RL, Olson JG, Perkins BA, Bibb W. Serological response to \"Rochalimaea henselae\" antigen in suspected cat-scratch disease. Lancet 1992; 339:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/7\">",
"      Zangwill KM, Hamilton DH, Perkins BA, et al. Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med 1993; 329:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/8\">",
"      Szelc-Kelly CM, Goral S, Perez-Perez GI, et al. Serologic responses to Bartonella and Afipia antigens in patients with cat scratch disease. Pediatrics 1995; 96:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/9\">",
"      La Scola B, Liang Z, Zeaiter Z, et al. Genotypic characteristics of two serotypes of Bartonella henselae. J Clin Microbiol 2002; 40:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/10\">",
"      Kordick DL, Hilyard EJ, Hadfield TL, et al. Bartonella clarridgeiae, a newly recognized zoonotic pathogen causing inoculation papules, fever, and lymphadenopathy (cat scratch disease). J Clin Microbiol 1997; 35:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/11\">",
"      Giladi M, Avidor B, Kletter Y, et al. Cat scratch disease: the rare role of Afipia felis. J Clin Microbiol 1998; 36:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/12\">",
"      Tappero JW, Koehler JE, Berger TG, et al. Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med 1993; 118:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/13\">",
"      Jacomo V, Kelly PJ, Raoult D. Natural history of Bartonella infections (an exception to Koch's postulate). Clin Diagn Lab Immunol 2002; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/14\">",
"      Dehio C. Molecular and cellular basis of bartonella pathogenesis. Annu Rev Microbiol 2004; 58:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/15\">",
"      Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection. Pediatrics 2008; 121:e1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/16\">",
"      Hamilton DH, Zangwill KM, Hadler JL, Cartter ML. Cat-scratch disease--Connecticut, 1992-1993. J Infect Dis 1995; 172:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/17\">",
"      Ridder GJ, Boedeker CC, Technau-Ihling K, et al. Role of cat-scratch disease in lymphadenopathy in the head and neck. Clin Infect Dis 2002; 35:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/18\">",
"      Tan TQ, Wagner ML, Kaplan SL. Bartonella (Rochalimaea) henselae hepatosplenic infection occurring simultaneously in two siblings. Clin Infect Dis 1996; 22:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/19\">",
"      Windsor JJ. Cat-scratch disease: epidemiology, aetiology and treatment. Br J Biomed Sci 2001; 58:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/20\">",
"      Jackson LA, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health 1993; 83:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/21\">",
"      Ben-Ami R, Ephros M, Avidor B, et al. Cat-scratch disease in elderly patients. Clin Infect Dis 2005; 41:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/22\">",
"      Apalsch AM, Nour B, Jaffe R. Systemic cat-scratch disease in a pediatric liver transplant recipient and review of the literature. Pediatr Infect Dis J 1993; 12:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/23\">",
"      Bonatti H, Mendez J, Guerrero I, et al. Disseminated Bartonella infection following liver transplantation. Transpl Int 2006; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/24\">",
"      Thudi KR, Kreikemeier JT, Phillips NJ, et al. Cat scratch disease causing hepatic masses after liver transplant. Liver Int 2007; 27:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/25\">",
"      Bhatti Z, Berenson CS. Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infect Dis 2007; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/26\">",
"      Koehler JE, Glaser CA, Tappero JW. Rochalimaea henselae infection. A new zoonosis with the domestic cat as reservoir. JAMA 1994; 271:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/27\">",
"      Chomel BB, Kasten RW, Floyd-Hawkins K, et al. Experimental transmission of Bartonella henselae by the cat flea. J Clin Microbiol 1996; 34:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/28\">",
"      Chomel BB, Abbott RC, Kasten RW, et al. Bartonella henselae prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers. J Clin Microbiol 1995; 33:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/29\">",
"      Foley JE, Chomel B, Kikuchi Y, et al. Seroprevalence of Bartonella henselae in cattery cats: association with cattery hygiene and flea infestation. Vet Q 1998; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/30\">",
"      Moriarty RA, Margileth AM. Cat scratch disease. Infect Dis Clin North Am 1987; 1:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/31\">",
"      Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985; 139:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/32\">",
"      Sander A, Frank B. Paronychia caused by Bartonella henselae. Lancet 1997; 350:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/33\">",
"      Lenoir AA, Storch GA, DeSchryver-Kecskemeti K, et al. Granulomatous hepatitis associated with cat scratch disease. Lancet 1988; 1:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/34\">",
"      Delahoussaye PM, Osborne BM. Cat-scratch disease presenting as abdominal visceral granulomas. J Infect Dis 1990; 161:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/35\">",
"      Fretzayas A, Papadopoulos NG, Moustaki M, et al. Unsuspected extralymphocutaneous dissemination in febrile cat scratch disease. Scand J Infect Dis 2001; 33:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/36\">",
"      Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/37\">",
"      Margileth AM, Wear DJ, English CK. Systemic cat scratch disease: report of 23 patients with prolonged or recurrent severe bacterial infection. J Infect Dis 1987; 155:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/38\">",
"      Hipp SJ, O'Shields A, Fordham LA, et al. Multifocal bone marrow involvement in cat-scratch disease. Pediatr Infect Dis J 2005; 24:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/39\">",
"      Tsujino K, Tsukahara M, Tsuneoka H, et al. Clinical implication of prolonged fever in children with cat scratch disease. J Infect Chemother 2004; 10:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/40\">",
"      Jacobs RF, Schutze GE. Bartonella henselae as a cause of prolonged fever and fever of unknown origin in children. Clin Infect Dis 1998; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/41\">",
"      Cunningham ET, Koehler JE. Ocular bartonellosis. Am J Ophthalmol 2000; 130:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/42\">",
"      Wear DJ, Malaty RH, Zimmerman LE, et al. Cat scratch disease bacilli in the conjunctiva of patients with Parinaud's oculoglandular syndrome. Ophthalmology 1985; 92:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/43\">",
"      Ridder GJ, Boedeker CC, Technau-Ihling K, Sander A. Cat-scratch disease: Otolaryngologic manifestations and management. Otolaryngol Head Neck Surg 2005; 132:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/44\">",
"      Grando D, Sullivan LJ, Flexman JP, et al. Bartonella henselae associated with Parinaud's oculoglandular syndrome. Clin Infect Dis 1999; 28:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/45\">",
"      Bhatti MT, Asif R, Bhatti LB. Macular star in neuroretinitis. Arch Neurol 2001; 58:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/46\">",
"      Suhler EB, Lauer AK, Rosenbaum JT. Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. Ophthalmology 2000; 107:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/47\">",
"      Reed JB, Scales DK, Wong MT, et al. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology 1998; 105:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/48\">",
"      Albini TA, Lakhanpal RR, Foroozan R, Holz ER. Macular hole in cat scratch disease. Am J Ophthalmol 2005; 140:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/49\">",
"      Marra CM. Neurologic complications of Bartonella henselae infection. Curr Opin Neurol 1995; 8:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/50\">",
"      Selby G, Walker GL. Cerebral arteritis in cat-scratch disease. Neurology 1979; 29:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/51\">",
"      Baylor P, Garoufi A, Karpathios T, et al. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease). Clin Infect Dis 2007; 45:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/52\">",
"      Maman E, Bickels J, Ephros M, et al. Musculoskeletal manifestations of cat scratch disease. Clin Infect Dis 2007; 45:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/53\">",
"      Giladi M, Maman E, Paran D, et al. Cat-scratch disease-associated arthropathy. Arthritis Rheum 2005; 52:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/54\">",
"      Hajjaji N, Hocqueloux L, Kerdraon R, Bret L. Bone infection in cat-scratch disease: a review of the literature. J Infect 2007; 54:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/55\">",
"      Ridder GJ, Technau-Ihling K, Sander A, Boedeker CC. Spectrum and management of deep neck space infections: an 8-year experience of 234 cases. Otolaryngol Head Neck Surg 2005; 133:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/56\">",
"      Baorto E, Payne RM, Slater LN, et al. Culture-negative endocarditis caused by Bartonella henselae. J Pediatr 1998; 132:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/57\">",
"      Angelakis E, Pulcini C, Waton J, et al. Scalp eschar and neck lymphadenopathy caused by Bartonella henselae after Tick Bite. Clin Infect Dis 2010; 50:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/58\">",
"      Bosch X. Hypercalcemia due to endogenous overproduction of active vitamin D in identical twins with cat-scratch disease. JAMA 1998; 279:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/59\">",
"      Klein JD. Cat scratch disease. Pediatr Rev 1994; 15:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/60\">",
"      Rolain JM, Lepidi H, Zanaret M, et al. Lymph node biopsy specimens and diagnosis of cat-scratch disease. Emerg Infect Dis 2006; 12:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/61\">",
"      Margileth AM. Recent Advances in Diagnosis and Treatment of Cat Scratch Disease. Curr Infect Dis Rep 2000; 2:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/62\">",
"      Bergmans AM, Peeters MF, Schellekens JF, et al. Pitfalls and fallacies of cat scratch disease serology: evaluation of Bartonella henselae-based indirect fluorescence assay and enzyme-linked immunoassay. J Clin Microbiol 1997; 35:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/63\">",
"      Dupon M, Savin De Larclause AM, Brouqui P, et al. Evaluation of serological response to Bartonella henselae, Bartonella quintana and Afipia felis antigens in 64 patients with suspected cat-scratch disease. Scand J Infect Dis 1996; 28:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/64\">",
"      Sander A, Posselt M, Oberle K, Bredt W. Seroprevalence of antibodies to Bartonella henselae in patients with cat scratch disease and in healthy controls: evaluation and comparison of two commercial serological tests. Clin Diagn Lab Immunol 1998; 5:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/65\">",
"      Zbinden R, Michael N, Sekulovski M, et al. Evaluation of commercial slides for detection of immunoglobulin G against Bartonella henselae by indirect immunofluorescence. Eur J Clin Microbiol Infect Dis 1997; 16:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/66\">",
"      Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/67\">",
"      Jensen WA, Fall MZ, Rooney J, et al. Rapid identification and differentiation of Bartonella species using a single-step PCR assay. J Clin Microbiol 2000; 38:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23289/abstract/68\">",
"      Vermeulen MJ, Diederen BM, Verbakel H, Peeters MF. Low sensitivity of Bartonella henselae PCR in serum samples of patients with cat-scratch disease lymphadenitis. J Med Microbiol 2008; 57:1049.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5532 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23289=[""].join("\n");
var outline_f22_47_23289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Visceral organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Parinaud's oculoglandular syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neuroretinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Musculoskeletal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other atypical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5532|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/42/15010\" title=\"diagnostic image 1\">",
"      Abdomen CT of child with B henselae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5532|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/60/8128\" title=\"picture 1\">",
"      Cat scratch disease typical papular lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34814\" title=\"picture 2\">",
"      Enlarged lymph node in cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/62/32736\" title=\"picture 3\">",
"      Cat scratch macular star",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8182?source=related_link\">",
"      Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/40/35457?source=related_link\">",
"      Patient information: Cat scratch disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37925?source=related_link\">",
"      Treatment of cat scratch disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23290="External beam radiation therapy for localized prostate cancer";
var content_f22_47_23290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   External beam radiation therapy for localized prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Steven J DiBiase, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Mack Roach, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/47/23290/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/47/23290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard options for the initial treatment of men with clinically localized prostate cancer (ie, without distant metastases) include radiation therapy (external beam",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brachytherapy, with or without androgen deprivation therapy [ADT]), radical prostatectomy, or active surveillance in carefully selected patients. The choice of treatment is determined by a variety of factors including patient preference, physician judgment, and resource availability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no randomized trials that adequately compare radiation therapy (RT) with radical prostatectomy, observational data suggest that outcomes with either external beam RT or brachytherapy using adequate dosing schedules and contemporary conformal techniques are similar to radical prostatectomy when men with clinically localized prostate cancer are stratified based upon clinical tumor (T) stage, pretreatment serum PSA, and Gleason score.",
"   </p>",
"   <p>",
"    The use of external beam RT in the initial treatment of clinically localized prostate cancer will be reviewed here. The application of these techniques to men with low, intermediate, and high-risk prostate cancer is discussed separately, as is the role of brachytherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link\">",
"     \"Brachytherapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3132396\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of RT for men with localized prostate cancer is the delivery of a tumoricidal dose of radiation while minimizing radiation to surrounding normal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT planning must take into account the volume and anatomic distribution of both the tumor and normal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/2\">",
"     2",
"    </a>",
"    ]. The prostate gland is a midline structure that lies in close proximity to the rectum and bladder. Thus, the major toxicities of normal tissue irradiation are gastrointestinal and genitourinary.",
"   </p>",
"   <p>",
"    Definitive radiation therapy (RT) is usually delivered to the entire prostate gland because of the multifocal nature of prostate cancer and the inability to accurately localize all malignant areas within the gland by noninvasive means. Treatment fields are further individualized based upon the estimated risk of seminal vesicle and regional lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The lymphatic drainage of the prostate gland is through a periprostatic network that drains into both the external and internal iliac lymph nodes (together referred to as pelvic nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher clinical stage, serum PSA concentration, and Gleason score are associated with an increased risk of both seminal vesicle and pelvic lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The serum PSA and Gleason score have been incorporated into the anatomic stage prognostic groups of the 2010 TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). For patients at high risk of relapse, RT to the whole pelvis, which encompasses the bilateral lymph node regions, is sometimes utilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RT TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conformal techniques, particularly intensity modulated RT (IMRT), are the contemporary standard of care when external beam RT is used to treat localized prostate cancer. These conformal techniques allow higher doses to the target, while minimizing radiation to normal tissues compared with older, two dimensional-approaches. This improved targeting permits a decrease in toxicity and an improvement in therapeutic index [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Three-dimensional conformal RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional conformal RT (3D-CRT) delivers radiation to a three-dimensional volume using imaging studies and computer software to precisely target RT delivery by delineating the prostate gland and its surrounding structures. Because treatment margins are smaller than with older techniques, the volume of normal tissue receiving a clinically significant radiation dose is reduced.",
"   </p>",
"   <p>",
"    The prostate, rectum, and bladder are identified on axial pelvic CT images. Treatment planning computers then calculate the dose in three dimensions, and the beam arrangements are planned to the prostate target volume (the gross tumor volume, GTV) plus a margin of grossly normal surrounding tissue, termed the clinical target volume (CTV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/10\">",
"     10",
"    </a>",
"    ]. The planning target volume (PTV) is the final treatment volume that encompasses the GTV, CTV, and a margin for any error that results from daily set-up and prostatic motion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Either multileaf collimation or cerrobend blocks are used to shape the treatment portals. Dose-volume histograms, which are the visual representation of the dose received by a particular target volume, permit the radiation oncologist to assign a specific RT dose to a particular volume of tissue, maximizing the delivery of the highest doses to the areas at highest risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intensity-modulated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity-modulated RT (IMRT) is an advanced form of 3D-CRT that can create a dose distribution around a complex and irregular target volume (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72560 \" href=\"UTD.htm?7/28/7618\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54616 \" href=\"UTD.htm?11/53/12114\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/12\">",
"     12",
"    </a>",
"    ]. IMRT delivers non-uniform beam intensities to the target volume by changing the intensity of the beam, in contrast to 3D-CRT, in which a uniform intensity is administered to a defined field. The non-uniform beam intensity can be generated by varying the opening of the RT beam (collimator) with a fixed gantry position or by changing the beam opening during an arc [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/13\">",
"     13",
"    </a>",
"    ]. Alternatively, the beam intensity in IMRT can also be modulated by the gantry speed as in",
"    <span class=\"nowrap\">",
"     rotational/arc",
"    </span>",
"    delivery approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IMRT can safely escalate the dose to the prostate while reducing complications from irradiation of surrounding normal tissue, especially the rectum. The high degree of conformality of the RT field permits further dose escalation to the tumor target compared to 3D-CRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     IMRT versus 3D-CRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;IMRT is increasingly available in RT treatment centers; in the United States it has largely replaced older forms of 3D-CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/14\">",
"     14",
"    </a>",
"    ]. An important dosimetric advantage of IMRT may come from its application in treating pelvic lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/12,15-19\">",
"     12,15-19",
"    </a>",
"    ], where it allows better coverage of lymph nodes while reducing radiation to the rectum, colon, small bowel, bladder, and penile structures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials comparing IMRT with 3D-CRT. The toxicity profiles of 3D-CRT and IMRT were compared in an analysis of over 12,000 men treated for localized prostate cancer identified from the Medicare Surveillance, Epidemiology, and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, IMRT was associated with less gastrointestinal morbidity and fewer hip fractures but with a higher frequency of erectile dysfunction.",
"   </p>",
"   <p>",
"    These differences may be partially explained based upon differences in dosing. In observational studies, IMRT appears to be less toxic at an equivalent dose but more toxic when it is used to escalate doses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single institution series 172 consecutive men received whole pelvis RT using either 3D-CRT or IMRT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/21\">",
"       21",
"      </a>",
"      ]. The total doses to the pelvic lymph nodes and prostatic bed were approximately 50 Gy and 72 Gy, respectively, with each treatment technique. Grade 2 or greater acute upper gastrointestinal toxicity (diarrhea, mucous), lower gastrointestinal toxicity (rectal pain, intermittent bleeding), and urinary symptoms (frequency, urgency, nocturia) were all lower with IMRT (12 versus 7, 9 versus 3, and 22 versus 7 percent, respectively).",
"     </li>",
"     <li>",
"      In a single-institution series of 1571 men treated for localized prostate cancer, IMRT was used to treat 741 patients to a dose of 81 Gy, while 830 men were treated with 3D-CRT at lower doses (358 at &le;70.2 Gy and 472 at 75.6 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/22\">",
"       22",
"      </a>",
"      ]. Acute urinary symptoms requiring treatment were significantly more frequent with IMRT than 3D-CRT (37 versus 22 percent), while acute rectal symptoms were uncommon with either modality (3 and 1 percent, respectively). Late urinary tract toxicity (frequency or urgency, incontinence, hematuria, stricture) was significantly more frequent in patients treated with IMRT (20 versus 12 percent). Patients treated with IMRT had a significantly decreased frequency of grade &ge;2 gastrointestinal toxicity at 10 years (5 versus 13 percent with 3D-CRT).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Image-guided RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Image-guided radiation therapy (IGRT) is a technique that acquires two- or three-dimensional images prior to each treatment, thus tracking the location of the tumor and surrounding organs. Commonly used imaging approaches for prostate IGRT include gold marker (fiducial) tracking with megavoltage portal imaging, fluoroscopy, abdominal ultrasound, or CT. IGRT provides accurate localization of the prostate gland, which can vary on a daily basis.",
"   </p>",
"   <p>",
"    Over the last several years, the use of IGRT in prostate cancer RT has grown substantially. Most investigators have concluded that IGRT allows treating clinicians to reduce target volumes and may be useful to reduce treatment related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Definitive evidence that IGRT reduces morbidity and improves the efficacy of prostate cancer treatment will require carefully conducted clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Particle irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particle beams interact more densely with tissue, causing greater levels of ionization per unit length and an increased radiobiologic effect (RBE) compared with photons, which lack mass and charge. The most extensive data are available for particle beams using protons; there is more limited, ongoing research with carbon ions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920638\">",
"    <span class=\"h3\">",
"     Proton beam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical advantage of proton beam therapy is in its dose distribution. The physical characteristics of the proton beam result in the majority of the energy being deposited at the end of a linear track, in what is called the Bragg peak. The radiation dose then falls rapidly to zero beyond the Bragg peak. However, there can be some uncertainty about the exact location of the Bragg peak due to tissue inhomogeneities (eg, bone, air). Proton beam therapy thus permits the delivery of high doses of RT to the target volume while limiting the \"scatter\" dose received by surrounding tissues.",
"   </p>",
"   <p>",
"    Use of proton beam RT is expanding, as more proton beam treatment centers open. However, there are no randomized trials that compare proton beam therapy with photon beam therapy or brachytherapy in men with clinically localized prostate cancer.",
"   </p>",
"   <p>",
"    The most extensive data come from studies in which a combination of proton beam therapy and external beam RT was used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. These studies have confirmed the value of high doses of RT. However, retrospective analyses have not established whether proton beam therapy (either alone or in combination with photon therapy) is either more effective or less toxic than photon therapy alone (especially IMRT) or brachytherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis from the Medicare Surveillance, Epidemiology, and End Results (SEER) database identified 684 men treated with proton beam therapy between 2002 and 2007 and compared these with a cohort treated using IMRT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/14\">",
"       14",
"      </a>",
"      ]. IMRT was associated with significantly less gastrointestinal morbidity. However, there were no significant statistically significant differences in other toxicities, nor was there a significant difference in the frequency with which patients required additional cancer therapy.",
"     </li>",
"     <li>",
"      A retrospective analysis of early toxicity compared 421 men treated for prostate cancer with proton beam therapy with 842 matched controls treated with IMRT in the Medicare database [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients were treated during 2008-2009. There was a statistically significant decrease in genitourinary toxicity at six months, but this difference had disappeared by one year. There were no other significant differences in toxicity between the two techniques at either six months or one year. The costs associated with proton beam therapy were approximately 75 percent higher compared with IMRT.",
"     </li>",
"     <li>",
"      Another analysis compared outcomes in patients with localized prostate cancer treated between 1996 and 1999 with high dose radiation using photons plus proton beam or brachytherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/29\">",
"       29",
"      </a>",
"      ]. There was no difference in the primary outcome, biochemical progression free survival.",
"     </li>",
"     <li>",
"      A systematic review of the available evidence from the American Society of Radiation Oncology (ASTRO) on efficacy and toxicity concluded that outcomes were similar with proton beam therapy and IMRT, but did not demonstrate a benefit for the proton beam approach [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H920645\">",
"    <span class=\"h3\">",
"     Carbon ion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon ion RT is being evaluated in a series of studies in Japan as an alternative form of particle irradiation to treat men with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a phase II study, 175 men with prostate cancer were treated with 66 GyE in 20 fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/33\">",
"     33",
"    </a>",
"    ]. Radiation was given as monotherapy in men with low-risk disease and with ADT for those with high-risk disease. The biochemical relapse-free survival rates were 87 and 88 percent in low and high-risk patients at a median follow-up of 46 months. Serious toxicity was uncommon. The results are similar to studies using conventional RT. Longer follow-up and direct comparisons are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3127128\">",
"    <span class=\"h2\">",
"     Stereotactic body RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is an extreme form of hypofractionation, in which the entire dose of radiation is administered in one or a very limited number of fractions. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hypofractionation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H2#H2\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results with SBRT in limited numbers of patients with low-risk prostate cancer suggest that this approach is feasible and has comparable efficacy and safety to other forms of definitive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, longer follow-up in larger numbers of patients is required to establish the safety and efficacy of this approach; at present SBRT should only be performed within the context of a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3132687\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial choice of treatment approach and the interpretation of outcomes in men with localized prostate cancer requires stratification for known pretreatment prognostic factors, including clinical stage (tumor [T], lymph node [N], metastasis [M]), serum PSA, and Gleason score (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In brief, low-, intermediate-, and high-risk groups are defined as follows (",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk - AJCC clinical stage T1c or T2a, PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and biopsy Gleason score &le; 6. This corresponds to the anatomic stage prognostic group I in the 2010 TNM staging system.",
"     </li>",
"     <li>",
"      Intermediate-risk - AJCC clinical stage T2b, or PSA between 10 and 20",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      or biopsy Gleason score 7. This corresponds to the anatomic stage prognostic group IIA in the 2010 TNM staging system.",
"     </li>",
"     <li>",
"      High-risk - AJCC clinical stage T2c disease, or PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      or biopsy Gleason score of 8 or higher. This corresponds to the anatomic stage prognostic group IIB in the 2010 TNM staging system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation and treatment options appropriate to each risk category are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=see_link\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3125082\">",
"    <span class=\"h2\">",
"     Assessment of treatment efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the success of treatment was defined by the absence of local progression (by physical examination or prostatic biopsies), distant metastases, or cancer-related death. Now, a rising serum PSA following RT is now almost universally used as an end point for treatment failure and is termed biochemical recurrence. Men without a rise in serum PSA following treatment are considered biochemically without evidence of disease (bNED). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3124870\">",
"    <span class=\"h3\">",
"     Biochemical recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following radical prostatectomy, the serum level of PSA should become undetectable, since all normal prostate tissue as well as the tumor is removed. Although in principle this should render a straightforward definitive endpoint, in fact there is no consensus as to what constitutes a failure after surgery. Most series use a PSA &gt;0.2",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    but ultra-sensitive assays can reliably detect recurrences years earlier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H5#H5\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition of biochemical failure after definitive RT is complicated by the presence of normal prostatic",
"   </p>",
"   <p>",
"    glandular tissue remains following RT. Furthermore, the decline in serum PSA following RT is gradual, and the mean time for the PSA to reach its nadir is 18 months or longer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H6#H6\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an effort to standardize the criteria used to define progression, a consensus panel convened by the American Society for Radiation Oncology (ASTRO) in 1996 established criteria for defining biochemical failure in patients who had been treated with external beam RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/37\">",
"     37",
"    </a>",
"    ]. These criteria were modified by ASTRO in 2005 as the so-called Phoenix criteria, which are now widely used for patients treated with radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H4#H4\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Definition of biochemical progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The \"Phoenix\" criteria define biochemical (PSA) failure as a rise in serum PSA of 2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or more above the nadir, regardless of whether or not a patient receives androgen deprivation therapy. The date of failure is defined by the time the rise in the PSA by &ge;2",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    above the nadir is observed. This definition however was not designed to determine cure rates but rather the presence of a clinically significant recurrence and thus, should not be used to compare with other modalities. &nbsp;",
"   </p>",
"   <p>",
"    Although biochemical progression is universally accepted as an endpoint to define treatment failure, overt metastatic disease may not become evident for many years after a rising serum PSA is detected. The natural history of disease in men with an isolated rising serum PSA without clinical evidence of metastases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3124877\">",
"    <span class=\"h3\">",
"     Posttreatment biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate rebiopsy is not a routine component of follow-up after primary treatment with RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H11086744#H11086744\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Surveillance strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rebiopsy is only indicated if the serum PSA is rising and further local therapy is being considered, since some of these men are curable with salvage retreatment (eg, surgery, brachytherapy, cryosurgery). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=see_link\">",
"     \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time course of disappearance of viable cancer from the prostate following RT can be prolonged. This is thought to be due to the long doubling time of many prostate tumors and the observation that cell death following RT is a postmitotic event. As a result, false positive biopsies may be due to delayed tumor regression, and indeterminate biopsies (showing either atypical cells or radiation effect in tumor cells) are of uncertain significance. Nonetheless, the persistence of viable-appearing tumor cells beyond 18 months does appear to predict a greater likelihood of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic changes induced by RT and the difficulty in accurate interpretation of a prostate biopsy following RT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H29#H29\">",
"     \"Interpretation of prostate biopsy\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conformal RT techniques permit escalation of radiation doses to the prostate gland beyond the lower doses used with older techniques. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Three-dimensional conformal RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A meta-analysis incorporated data from seven well-designed randomized trials that included 2812 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/42\">",
"     42",
"    </a>",
"    ]. The incidence of biochemical failure after treatment with 74 to 80 Gy was significantly lower than with doses of 64 to 70 Gy (25 versus 35 percent, odds ratio 0.60, 95% CI 0.47-0.76). The decreased risk of biochemical recurrence was significant for low, intermediate, and high-risk patients. However, there was no evidence that mortality was improved with higher doses of RT. In the five studies that included mortality as an outcome, overall and prostate cancer specific mortality rates were similar in the two groups (14.4 versus 14.1 and 4.9 versus 6.1 percent, respectively). These conclusions were consistent with those of a literature review conducted by the American Society for Radiation Oncology (ASTRO), which compared dose escalation using 3D-CRT with lower doses using older techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer techniques (IMRT, IGRT, proton beam irradiation, combining external beam RT with brachytherapy) have allowed further dose escalation, and doses greater than 81 Gy can be safely administered to the prostate gland [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/43\">",
"     43",
"    </a>",
"    ]. These different approaches have not been compared in randomized trials. Whether these higher doses improve efficacy remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to total dose, the overall treatment time may be a significant factor influencing the rate of biochemical failure. In a multicenter, retrospective analysis of 4338 men treated with EBRT for T1 or T2 prostate cancer in the PSA era, a statistically significant decrease in biochemical failure was seen with shorter treatment duration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/46\">",
"     46",
"    </a>",
"    ]. This effect was limited to cases in which the total radiation dose was &ge;70 Gy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypofractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shorter courses of RT using larger treatment fractions are being evaluated for the treatment of localized prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Three randomized trials have yielded equivocal results, although each is subject to important limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest trial, 936 men with early stage prostate cancer were randomly assigned to conventional fractionation (64 to 66 Gy in 32 or 33 fractions) or a hypofractionated schedule (52.5 to 55 Gy in 20 fractions). At a median follow-up of 5.7 years, conventional fractionation appeared to be superior to the hypofractionated regimen (biochemical or clinical failure rate 53 versus 60 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/47\">",
"       47",
"      </a>",
"      ]. However, the total radiation dose was too low by contemporary standards on both arms. Another trial, using essentially the same dosing schedules in 457 patients, found no significant differences in toxicity at the two-year assessment with the shortened dose schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 217 men were randomly assigned to a hypofractionated or conventional RT schedule (55 Gy in 20 fractions or 64 Gy in 32 fractions) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/52\">",
"       52",
"      </a>",
"      ]. With 7.5 years of follow-up, the hypofractionated regimen yielded a significantly improved freedom from biochemical relapse based upon the Phoenix criteria (53 versus 34 percent at 7.5 years), but not the ASTRO criteria (44 percent on both treatment arms). As in the previous trial, the total radiation doses were low by contemporary standards. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H6#H6\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A third trial in 168 men with high-risk prostate cancer used higher doses of conformal RT (80 Gy in 40 fractions over eight weeks versus 62 Gy in 20 fractions over five weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/50,53,54\">",
"       50,53,54",
"      </a>",
"      ]. The incidence of toxicity, the primary objective of the trial, was similar with the two schedules. In the most recent analysis of this trial, there was no significant difference in the five-year freedom from biochemical recurrence rate between the hypofractionation and conventional arms with a median follow-up of 70 months (85 and 79 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple randomized trials are ongoing, and long-term results are required before hypofractionation can be considered a standard alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Whole pelvis versus prostate only RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic status of the regional lymph nodes is typically unknown (NX) in men with clinically localized prostate cancer who are managed with RT. Various clinical and pathologic parameters have been used to estimate the likelihood of regional lymph node involvement and thus select patients for whole pelvis RT (WPRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of whole pelvis RT for men with intermediate- or high-risk disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H181128733#H181128733\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Prostate only versus whole pelvis RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3126101\">",
"    <span class=\"h2\">",
"     ADT with external beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of androgen deprivation therapy (ADT) in combination with external beam RT has become the standard of care for men receiving RT for high-risk prostate cancer, based upon improvements in cancer-specific and overall survival observed in multiple randomized trials. The results supporting the role of ADT in these patients and the specific details regarding duration and timing of ADT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H2956464#H2956464\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'External beam RT plus ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity of external beam RT is low in patients treated with contemporary techniques. In order to quantify treatment-related morbidity, the RTOG has developed physician report-based acute and late morbidity scales (",
"    <a class=\"graphic graphic_table graphicRef53812 \" href=\"UTD.htm?4/46/4844\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/58\">",
"     58",
"    </a>",
"    ]. Morbidity based upon patient-reported scores usually exceeds that reported by clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complications of external beam RT are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastrointestinal toxicity during RT can be manifested as proctitis or enteritis. The reported incidence of radiation proctitis ranges from 5 to 30 percent, depending upon the definition used, the dose of radiation, and the treatment volume.",
"   </p>",
"   <p>",
"    Symptoms include abdominal cramping, tenesmus, urgency, and frequency of defecation. They can usually be controlled with antidiarrheal agents or topical antiinflammatory preparations. After RT is completed, acute symptoms usually resolve within three to eight weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term gastrointestinal side effects persist in a low percentage of patients, and can be manifested by persistent diarrhea, tenesmus, rectal urgency, or hematochezia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Rectal or anal strictures, fecal incontinence, ulcers, and perforation are rare. In several large trials, the incidence of grade 3 or greater toxicity in men treated with high-dose RT (&ge;74 Gy) was 1 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/25,62-65\">",
"     25,62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, when highly conformal RT beams are used and the dose to the rectum is limited, the rate of moderate to severe gastrointestinal effects with high-dose RT approaches is similar to that seen among men who receive lower doses of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/62-64,66\">",
"     62-64,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Urinary symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;During external beam RT, approximately one-half of patients experience urinary symptoms, which may include frequency, dysuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urgency due to cystitis, urethritis, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/25,62-65\">",
"     25,62-65",
"    </a>",
"    ]. Symptoms typically resolve within four weeks after the completion of therapy.",
"   </p>",
"   <p>",
"    Late urinary tract side effects are relatively uncommon in contemporary series. The incidence of urinary incontinence is probably about 1 percent in men without a history of prior prostate surgery, although this may vary depending upon definition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/59,60,67-69\">",
"     59,60,67-69",
"    </a>",
"    ]. In patients who had severe obstructive or irritative symptoms prior to treatment, external beam RT may eventually improve functional status, presumably by decreasing prostate size [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other long-term genitourinary toxicity includes urethral strictures, cystitis, hematuria, and bladder contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/71\">",
"     71",
"    </a>",
"    ]. In a review of two RTOG randomized trials, the incidence of grade 3 or worse late GU toxicity was 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/72\">",
"     72",
"    </a>",
"    ]. One-half of these were attributed to urethral stricture that could be managed with outpatient dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Risk of hemorrhage in anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who are on anticoagulation appear to be at increased risk of hemorrhage from either radiation cystitis or radiation proctitis. In a single-institution, retrospective series of 568 men treated with definitive external beam RT (either 3D-CRT or IMRT), the four-year risk of grade 3 or worse bleeding was significantly higher among the 79 men on either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    compared to those not anticoagulated (15.5 versus 3.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/73\">",
"     73",
"    </a>",
"    ]. Gastrointestinal bleeding was more common that urinary tract bleeding. Such bleeding is generally self-limited and rarely requires transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the frequency of erectile dysfunction in men treated with RT has been studied extensively.",
"   </p>",
"   <p>",
"    A validated model has been developed to help predict the probability of erectile function two years after external beam RT; significant factors in this analysis included planned neoadjuvant hormone therapy (yes or no), pretreatment PSA level (&lt;4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    versus &ge;4",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    and the pretreatment sexual health related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3126101\">",
"     'ADT with external beam RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The frequency of new onset impotence following external beam RT depends in part upon the definition of potency and on the time frame of assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/59\">",
"     59",
"    </a>",
"    ]. In contemporary series, 30 to 45 percent of men who are potent prior to RT become impotent after therapy, with the frequency increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/67,68,75\">",
"     67,68,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technical aspects of RT delivery may contribute to RT-induced impotence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. This literature suggests that the risk of impotence is significantly reduced if penile structures (particularly the corpus spongiosum) are avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/76\">",
"     76",
"    </a>",
"    ]. More sophisticated forms of radiation delivery, such as IMRT, may limit the dose to the penile bulb and corporal bodies compared to three-dimensional conformal RT (3D-CRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Intensity-modulated RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Phosphodiesterase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ) may be more effective in men with erectile dysfunction after RT than after radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. In one representative series, sildenafil was administered once weekly (100 mg) to 30 men with postradiation erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/81\">",
"     81",
"    </a>",
"    ]. During the study, 76 percent reported improved erectile function, which permitted at least one successful attempt at intercourse per week. The time course of response was gradual, with 40, 57, 66, 69, and 74 percent of patients responding at weeks 1 through 5, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is common following RT. Prospective studies have shown that fatigue is present prior to treatment in men with prostate cancer, and its incidence and severity increase during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Two randomized trials found that aerobic and resistance exercise ameliorated fatigue in the short term, and resistance exercise may offer additional conditioning benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link&amp;anchor=H9#H9\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Insufficiency fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insufficiency fractures are a subtype of stress fracture that can result from physiologic stress to weakened bone. These uncommonly occur following external beam RT for prostate cancer. These fractures are thought to be due to radiation injury to the microcirculation in bone.",
"   </p>",
"   <p>",
"    In a retrospective series of 134 patients treated for prostate cancer, clinically symptomatic insufficiency fractures were diagnosed in eight (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/89\">",
"     89",
"    </a>",
"    ]. All had been treated with whole pelvis 3D-CRT or IMRT for locally advanced disease or positive regional lymph nodes. Seven of the eight had also been treated with androgen deprivation therapy (ADT), which may have contributed to the risk of insufficiency fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients presented with low back or pelvic pain and were diagnosed at a median of 20 months after RT. On imaging studies, all had fractures in the sacrum, and pubic bone involvement was present as well in two cases. All patients were managed with rest and analgesics.",
"   </p>",
"   <p>",
"    None of the patients had biochemical or imaging evidence of metastatic disease when they presented with insufficiency fractures or during subsequent follow-up (median 40 months). Characteristic findings on imaging studies may be useful in distinguishing insufficiency fractures from bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies suggest that there is an increased risk of second malignancies following RT for localized prostate cancer, although the magnitude of this effect is small [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. These retrospective studies do not account for the dose of radiation or the impact factors such as tobacco use may have on the risk of a second malignancy. The most commonly implicated malignancies are bladder and rectal cancer.",
"   </p>",
"   <p>",
"    The magnitude of this risk and its relationship to the type of RT is illustrated by a series from the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/91\">",
"     91",
"    </a>",
"    ]. In this study, the risk of a second malignancy was analyzed in 243,000 men treated for prostate cancer with either RT or radical prostatectomy between 1988 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/91\">",
"     91",
"    </a>",
"    ]. The relative risks [RRs] of developing bladder cancer for those treated with EBRT, brachytherapy, and combined EBRT plus brachytherapy compared to radical prostatectomy were 1.88, 1.52, and 1.85, respectively. Although these differences were statistically significant, the absolute increase in the risk of bladder cancer was approximately 1 percent at 10 years compared to patients managed with radical prostatectomy. The increased risk of rectal cancer was less pronounced (RR 1.26 with EBRT alone).",
"   </p>",
"   <p>",
"    Although RT appears to be associated with a small increase in the incidence of cancer, the risk of dying from a secondary malignancy at 10 to 15 years is very small and appears to be of similar magnitude to the perioperative mortality associated with radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. Furthermore, at least one observational study suggests that the risk of a second malignancy is less pronounced with newer RT techniques (3D-CRT, IMRT) compared with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/47/23290/abstract/99\">",
"     99",
"    </a>",
"    ]. Longer follow-up will be required to provide a more definitive estimate of this risk with newer techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3127243\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RT VERSUS OTHER MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that provide adequate data to compare external beam RT versus other treatment modalities as initial therapy in men with localized prostate cancer. Data from large observational series suggest that oncologic efficacy with external beam RT is similar to other approaches, and the choice of therapy is based upon a combination of factors including treatment-related complications and patient preferences. These results are discussed separately for the different risk groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H11496867#H11496867\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link&amp;anchor=H1191259#H1191259\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4111988\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies after treatment for localized prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H7449313#H7449313\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Localized prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       \"Patient information: Radiation therapy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=see_link\">",
"       \"Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy (external beam or brachytherapy), radical prostatectomy, and, in selected cases, active surveillance are standard treatment options for men with localized prostate cancer. The choice of external beam RT is largely a matter of patient preference. There are no randomized trials that compare RT with radical prostatectomy. Long-term outcomes with contemporary external beam RT techniques that use high radiation doses and conformal treatment planning, as well as neoadjuvant androgen deprivation therapy (ADT) for those with higher-risk disease, appear similar to those with surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The anatomic extent of disease, serum PSA level, and biopsy Gleason grade are used for risk stratification. Patients with low risk disease can be treated with external beam RT alone, while those at higher risk of recurrence may benefit from the addition of androgen deprivation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients choosing external beam RT, treatment should be administered with a contemporary, three-dimensional conformal technique. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'External beam RT techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If intensity-modulated radiation therapy (IMRT) is available, we suggest its use, particularly in men in whom pelvic nodal irradiation is being considered (ie, those with a predicted risk of pelvic nodal metastases of 15 percent or higher) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Retrospective analyses do not provide evidence that proton beam therapy is either more effective or less toxic than photon therapy alone. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intensity-modulated RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When available, we suggest image-guided radiation therapy (IGRT) for daily localization of the prostate prior to each treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Image-guided RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An adequate dose of radiation is necessary for optimal tumor control. We prefer a dose of 74 Gy or higher. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of external beam RT is assessed using the Phoenix criteria, which define biochemical recurrence as a rise in the serum PSA of 2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or more above the nadir, regardless of whether or not a patient receives androgen deprivation therapy. The date of failure is defined by the time the rise in the PSA by &ge;2",
"      <span class=\"nowrap\">",
"       ng/ml",
"      </span>",
"      is noted. (See",
"      <a class=\"local\" href=\"#H3124870\">",
"       'Biochemical recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent complications due to external beam RT are gastrointestinal (radiation proctitis and enteritis), urinary (frequency, dysuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urgency due to cystitis, urethritis), and sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/1\">",
"      Pollack JM. Radiation therapy options in the treatment of prostate cancer. Cancer Invest 2000; 18:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/2\">",
"      McLaughlin PW, Troyer S, Berri S, et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 2005; 63:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/3\">",
"      Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/4\">",
"      Stephenson JA, Wiley AL Jr. Current techniques in three-dimensional CT simulation and radiation treatment planning. Oncology (Williston Park) 1995; 9:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/5\">",
"      Raboy A, Adler H, Albert P. Extraperitoneal endoscopic pelvic lymph node dissection: a review of 125 patients. J Urol 1997; 158:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/6\">",
"      Whitmore WF 3rd, Blute RD Jr, Kaplan WD, Gittes RF. Radiocolloid scintigraphic mapping of the lymphatic drainage of the prostate. J Urol 1980; 124:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/7\">",
"      D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/8\">",
"      Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/9\">",
"      Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 2005; 62:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/10\">",
"      Bedford JL, Khoo VS, Webb S, Dearnaley DP. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2000; 46:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/11\">",
"      Melian E, Mageras GS, Fuks Z, et al. Variation in prostate position quantitation and implications for three-dimensional conformal treatment planning. Int J Radiat Oncol Biol Phys 1997; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/12\">",
"      Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/13\">",
"      De Neve W, Claus F, Van Houtte P, et al. [Intensity modulated radiotherapy with dynamic multileaf collimator. Technique and clinical experience]. Cancer Radiother 1999; 3:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/14\">",
"      Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012; 307:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/15\">",
"      Sanguineti G, Cavey ML, Endres EJ, et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? Int J Radiat Oncol Biol Phys 2006; 64:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/16\">",
"      Mangar SA, Huddart RA, Parker CC, et al. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005; 41:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/17\">",
"      Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004; 59:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/18\">",
"      Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part II. Br J Radiol 2004; 77:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/19\">",
"      Wang L, Hoban P, Paskalev K, et al. Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy. Med Dosim 2005; 30:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/20\">",
"      Wang-Chesebro A, Xia P, Coleman J, et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/21\">",
"      Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009; 93:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/22\">",
"      Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/23\">",
"      Singh J, Greer PB, White MA, et al. Treatment-related morbidity in prostate cancer: a&nbsp;comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys 2013; 85:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/24\">",
"      Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/25\">",
"      Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/26\">",
"      Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010; 28:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/27\">",
"      Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010; 303:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/28\">",
"      Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/29\">",
"      Coen JJ, Zietman AL, Rossi CJ, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 2012; 82:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/30\">",
"      Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012; 103:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/31\">",
"      Ishikawa H, Tsuji H, Kamada T, et al. Carbon-ion radiation therapy for prostate cancer. Int J Urol 2012; 19:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/32\">",
"      Okada T, Tsuji H, Kamada T, et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys 2012; 84:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/33\">",
"      Ishikawa H, Tsuji H, Kamada T, et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 2006; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/34\">",
"      Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010; 76:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/35\">",
"      King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/36\">",
"      Lee WR. Extreme hypofractionation for prostate cancer. Expert Rev Anticancer Ther 2009; 9:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/37\">",
"      Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/38\">",
"      Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/39\">",
"      Crook JM, Malone S, Perry G, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer 2009; 115:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/40\">",
"      Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002; 54:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/41\">",
"      Vance W, Tucker SL, de Crevoisier R, et al. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 2007; 67:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/42\">",
"      Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/43\">",
"      Lee WR. Seduced by dose? J Clin Oncol 2010; 28:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/44\">",
"      Speight JL, Roach M 3rd. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005; 23:8176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/45\">",
"      Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007; 68:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/46\">",
"      Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 2010; 96:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/47\">",
"      Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005; 23:6132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/48\">",
"      Yeoh EE, Fraser RJ, McGowan RE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003; 55:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/49\">",
"      Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/50\">",
"      Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/51\">",
"      Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/52\">",
"      Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011; 81:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/53\">",
"      Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/54\">",
"      Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/55\">",
"      Lee WR. The ethics of hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/56\">",
"      Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/57\">",
"      Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/58\">",
"      Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/59\">",
"      Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/60\">",
"      Shipley WU, Zietman AL, Hanks GE, et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 1994; 152:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/61\">",
"      Haddock MG, Sloan JA, Bollinger JW, et al. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol 2007; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/62\">",
"      Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/63\">",
"      Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005; 92:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/64\">",
"      Beckendorf V, Gu&eacute;rif S, Le Pris&eacute; E, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004; 60:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/65\">",
"      Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002; 54:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/66\">",
"      Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/67\">",
"      Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/68\">",
"      Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/69\">",
"      Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/70\">",
"      Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27:3916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/71\">",
"      Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007; 178:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/72\">",
"      Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/73\">",
"      Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys 2010; 76:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/74\">",
"      Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/75\">",
"      Mantz CA, Song P, Farhangi E, et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/76\">",
"      Roach M 3rd, Nam J, Gagliardi G, et al. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 2010; 76:S130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/77\">",
"      Fisch BM, Pickett B, Weinberg V, Roach M. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001; 57:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/78\">",
"      Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2004; 60:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/79\">",
"      Wernicke AG, Valicenti R, Dieva K, et al. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/80\">",
"      Buyyounouski MK, Horwitz EM, Price RA, et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 2004; 58:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/81\">",
"      Weber DC, Bieri S, Kurtz JM, Miralbell R. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999; 17:3444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/82\">",
"      Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999; 53:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/83\">",
"      Incrocci L, Koper PC, Hop WC, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001; 51:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/84\">",
"      Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/85\">",
"      Danjoux C, Gardner S, Fitch M. Prospective evaluation of fatigue during a course of curative radiotherapy for localised prostate cancer. Support Care Cancer 2007; 15:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/86\">",
"      Truong PT, Berthelet E, Lee JC, et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Can J Urol 2006; 13:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/87\">",
"      Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 2004; 101:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/88\">",
"      Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/89\">",
"      I��dem S, Al&ccedil;o G, Ercan T, et al. Insufficiency fractures after pelvic radiotherapy in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/90\">",
"      Kwon JW, Huh SJ, Yoon YC, et al. Pelvic bone complications after radiation therapy of uterine cervical cancer: evaluation with MRI. AJR Am J Roentgenol 2008; 191:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/91\">",
"      Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008; 180:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/92\">",
"      Bhojani N, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 2010; 76:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/93\">",
"      Margel D, Baniel J, Wasserberg N, et al. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg 2011; 254:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/94\">",
"      Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/95\">",
"      Herr HW, Carver B. Point: effect of radiation-associated second malignancies on prostate cancer survival. Urology 2008; 72:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/96\">",
"      Oh KS, Sandler HM. CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective. Urology 2008; 72:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/97\">",
"      Konety BR. Commentary on the etiologic relationship between prostate radiation and bladder cancer: the scourge for one is poison for the other. J Urol 2008; 179:S12.",
"     </a>",
"    </li>",
"    <li>",
"     Roach M. Editorial comment. J Urol 2008; 180:2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/47/23290/abstract/99\">",
"      Zelefsky MJ, Housman DM, Pei X, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83:953.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6946 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23290=[""].join("\n");
var outline_f22_47_23290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3132396\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTERNAL BEAM RT TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Three-dimensional conformal RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intensity-modulated RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - IMRT versus 3D-CRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Image-guided RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Particle irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H920638\">",
"      - Proton beam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H920645\">",
"      - Carbon ion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3127128\">",
"      Stereotactic body RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3132687\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FACTORS AFFECTING EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3125082\">",
"      Assessment of treatment efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3124870\">",
"      - Biochemical recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3124877\">",
"      - Posttreatment biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypofractionation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Whole pelvis versus prostate only RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3126101\">",
"      ADT with external beam RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Urinary symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Risk of hemorrhage in anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Insufficiency fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3127243\">",
"      EXTERNAL BEAM RT VERSUS OTHER MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4111988\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6946|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/28/7618\" title=\"diagnostic image 1\">",
"      IMRT prostate cancer target vol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6946|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/53/12114\" title=\"figure 1\">",
"      SMLC plan prostate IMRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 2\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/33/3612\" title=\"table 3\">",
"      Pretreat risk stratify prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/46/4844\" title=\"table 4\">",
"      RTOG LENT criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=related_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=related_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=related_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_47_23291="Primary secondary GN child";
var content_f22_47_23291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of glomerulonephritis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranous glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranoproliferative glomerulonephritis type I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membranoproliferative glomerulonephritis type II (dense deposit disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-glomerular basement membrane disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idioapthic crscentic glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secondary glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-streptococcal glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other post-infectious glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henoch-Sch&ouml;nlein purpura nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microscopic polyangiitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wegener granulomatosus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Reproduced with permission from: Niaudet, P. Nephritic Syndrome. In: Comprehensive Pediatric Nephrology, Geary, DF, Schaefer, F (Eds), Mosby, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23291=[""].join("\n");
var outline_f22_47_23291=null;
var title_f22_47_23292="Test results for bleeding disorders in children";
var content_f22_47_23292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected results of tests for hemostatic function in representative hemorrhagic disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        PT",
"       </td>",
"       <td class=\"subtitle1\">",
"        aPTT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fibrinogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculopathies, connective tissue diseases, or collagen disorders affecting skin",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal or increased*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        low",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Qualitative platelet abnormalities",
"       </td>",
"       <td>",
"        normal or low",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophilia A (factor VIII deficiency)",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        long",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        von Willebrand disease",
"       </td>",
"       <td>",
"        normal",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"       <td>",
"        normal or long",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"       <td>",
"        low",
"       </td>",
"       <td>",
"        long",
"       </td>",
"       <td>",
"        long",
"       </td>",
"       <td>",
"        low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PT: prothrombin time; aPTT: activated partial thromboplastin time.",
"     <br>",
"      * Fibrinogen may be elevated as an acute phase reactant in disorders of inflammation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The platelet count in myeloproliferative disorders is usually high (eg, essential thrombocythemia) and platelets may also be qualitatively abnormal, predisposing to hemorrhagic and thrombotic diatheses.",
"       <br>",
"        &Delta; The platelet count may be low in some patients with type 2B von Willebrand disease.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         The aPTT may be normal in those with Factor VIII activity &gt;40 percent.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23292=[""].join("\n");
var outline_f22_47_23292=null;
var title_f22_47_23293="Nasal vs intramuscular calcitonin bone pain";
var content_f22_47_23293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Nasal versus intramuscular calcitonin for bone pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of salmon calcitonin (sCT) on spontaneous bone pain in patients with recent osteoporotic fractures treated with either intranasal (100 Int. Units) or intramuscular (100 Int. Units) calcitonin. The intranasal calcitonin led to more effective pain relief.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gennari, C, Agnusdei, D, Camporeale, A, Calcif Tissue Int 1991; 49(Suppl 2):S9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23293=[""].join("\n");
var outline_f22_47_23293=null;
var title_f22_47_23294="NCCN risk factors for cutaneous SCC recurrence";
var content_f22_47_23294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83683%7EONC%2F78140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83683%7EONC%2F78140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features identified by the National Comprehensive Cancer Network as risk factors for recurrence of cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Location/size*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly-defined borders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressed patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Site of previous radiation therapy or chronic inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapidly growing tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderately or poorly differentiated tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoid (acantholytic), adenosquamous, or desmoplastic subtypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depth &ge;2 mm or Clark level IV or V",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineural or vascular involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Size &ge;20 mm on trunk or extremities; size &ge;10 mm on cheeks, forehead, scalp, or neck; size &ge;6 mm on \"mask areas\" of the face (central face, eyelids, eybrows, periorbital nose, lips [cutaneous and vermilion], chin, mandible, preauricular and postauricular skin/sulci, temple, ear, genitalia, hands, and feet).",
"    </div>",
"    <div class=\"reference\">",
"     Source: Miller SJ, Alam M, Anderson J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal Cell and Squamous Cell Skin Cancers, 2nd ed, National Comprehensive Cancer Network, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        Carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor 2 cm or less in greatest dimension with less than two high-risk features (see list of high-risk features below)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor greater than 2 cm in greatest dimension",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Tumor any size with two or more high-risk features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor with invasion of maxilla, mandible, orbit, or temporal bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        High-risk features for the primary tumor (T) staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Depth/invasion",
"       </td>",
"       <td colspan=\"3\">",
"        &gt;2 mm thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Clark level &ge;IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Perineural invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Anatomic location",
"       </td>",
"       <td colspan=\"3\">",
"        Primary site ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Primary site hair-bearing lip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Differentiation",
"       </td>",
"       <td colspan=\"3\">",
"        Poorly differentiated or undifferentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        N2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a lymph node, more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MI",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Stage IV",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Excludes cSCC of the eyelid.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Patients with primary cSCC or other cutaneous carcinomas with no evidence (clinical, radiologic, or pathologic) of regional or distant metastases are divided into two stages: Stage I for tumors measuring &le;2 cm in size and Stage II for those that are greater than 2 cm in size. In instances where there is clinical concern for extension of tumor into bone and radiologic evaluation has been performed (and is negative), these data may be included to support the Stage I vs. II designation. Tumors that are &le;2 cm in size can be upstaged to Stage II if they contain two or more high-risk features. Stage III patients are those with (1) clinical, histologic, or radiologic evidence of one solitary node measuring &le;3 cm in size or (2) tumor extension into bone: maxilla, mandible, orbit, or temporal bone. Stage IV patients are those with (1) tumor with direct or perineural invasion of skull base or axial skeleton, (2) &ge;2 lymph nodes or (3) single or multiple lymph nodes measuring &gt;3 cm in size or (4) distant metastasis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23294=[""].join("\n");
var outline_f22_47_23294=null;
var title_f22_47_23295="Fibrous pleural tumor IV CT";
var content_f22_47_23295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrous tumor of the pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 209px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADRAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XooooAKKWigAoopaAEopcUoGaAG0dOa07HRr28jMkFu8iL1xjitaz8Kz3k3lwunAyeR+PegDlzkmp7OxubyQJbQvKx5wozXaf2JpWmrEzzCWYDfIs4Cqo9D83NF94wWyeeLTmR1dQoCJhFGOxznNAFa08Aal9hN1flLUZwsbt8x554GfQ1qi28LaSmbn99Iig+WWHzN9Np4rjtQ8Qaheyl3mZSVC8dcYx1NZTEscscn1NAHpV38SRHGBpWnWtrjblVRdp29DjYP51nXvxEvbrczwIZSMbuAOnoBXC0tAHeaR4rMl1HFNqk1ikyFXl2khTz156c1P4y8e30t6LbR9ZvJLOP8AiH7tWb2w3IrzyloA6P8A4S3Vri9Se7vXkKkHa5JBHoc5zX1T+z9oVnB4JOtyw2817q0jSuzxq+xVJVVBK8DjJHvXxmK9k+B/xgfwTD/YmuQtc+H5JN6yRj97aM3VgP4k7levp6EA+spLGwk/1mnae/P8drGf/ZaqS6BoU3Mug6K/+/p8J/8AZab4f8R6H4msku9B1azvYJCQu2QRvkdtj4YfiK1iCjfMMYPIoAxj4U8MMct4Y8PN9dMgP/stZHiXwF4VvtLkRPC2hRzKNyNDYxxHPuVUGutLAZLdOtYOvXx2iKPcI+rOBx/KgDw+H4QW8+pG4urKxhtsnEKBuTngdvX+Vd5pXws8IKp+3eGdMkLjgfvVIP8A38robW9ga5BI2RjCqxIw30weDW8G8xQ2QAOmD1/WgDzHxP8ABHwhqmntDpNh/ZV8CcTwyOwBPTKsxBFfMfjjwnqXgzX5dK1iMCVRvjlTlJkPRlP+cGvuppXhKtIUYtwBXmf7Q/hH/hI/Az39pCp1DSibhSq/M0WPnXOM+/4UAfIBFGBSnn6UlAG14fOgyXAi16K8ihbpPauCQfcNxiuz1P4XLdWgvfCN8+o2zJvAcDcfXlePQfWvMq2PDviTUdBlJs5A0LffgkG5G/DtQBU1TR7/AEq4aHULWaCReMOhGaoEda9ah8ZaRr4K6to8EobHyDCspxzhuM54GKybrwdb6nBJLpkiW80K5aGRl5H13e/86APO8UVcvtPuLOVkmidSDjJFVCMGgBtLRRQAlGKWg0AJRS0UAFJS0UAGKKKKAAdaWk707jtQAmKUCjNLk0AGKO9PhieWRURSzMcAAZrttK8HvDAk+pMsfm8IpjYkHjP8PTmgDldM0q5v5gkMbY7naT/IV3uh+FbOC5tom2Xlw5DYA+UjrjnnP+Fd/wCFPBM/iKYDTrmKCNV8tikQ2qO5PAOfpXoGraH4U+E3hqbW9Wka5uMeXbxvgvPLjgIpOB6k9hzQB4N4g1WS2nj0yzjTzlGx5UGx16jGAccDisaTXRoMMtvDM8l2WOSkp+XI55DGsnxH4tvdY1G5u1H2Z7htzbGOR6DOfSubPOTnNAF7VdWvNTl3XU8sgHQO5bH51QHWiloAMUUUooAAKWiigAoopaAClFJSigBy8MGUkOOQwOCK+kP2b/E/iaay1NNRuLrUdHRkige5keQwydSEJzxgjIz6GvBfCugXnibXLfStNAE0uSzsDtjUdWbHb+uK+vvDGl2ehaBY6TpuwW9qgTcV+aVj1ZuOpPPtQB0lxqvmQ8sApBJxngfiK5fXdRnWMxqYmiIx5gfBxjPYj/Oal1O9SAqhMbyO33A4ycY6cjHUVHbQfaGff5Th2Kv/APWAb60AYdhfajclltm8yNMMsgYlWGewDeua7Pws1/JATqhUnPy7FIH179sUllaJZKAkpUDqojOMY6d6tx6kiFd0bKnYbevv0oAv3CRgK7KuevK9PpxVu3aN02OA6kYZex9qzbi4VrdixyB0AIFGmyncgVi4PJJPA/WgD4x+LPhZ/B/j3U9K4NuX8+2b1iflfy5H4Vxxr6q/aq8OJqHhCx8RRRKLjTZRBLJ3MMhwB+D/APoRr5WNADe9JTjSUACsUYMpIYdCK7Dwnq24GF3ZbpTuTDn5x3Uc9a4+gEqwKkgg5BHGKAPaFNjc2jLqFm8o5DGRD8wPT+D2689ua4TWtBhncyaWhiUfejkOcH0BwM1r+DvGNpM0Wm+JI0VJB5Y1DIUxjGAGAXke9aOpaJJps3+isbi3XgsJFxICeGGGoA8tuIXglaOQYdTgio69PubNtQWOwltbf7TkqrAl2f8Aujhj/k1xOuaHc6ZMVkjIz2wfl+vFAGNSU5lIJBGDSUAJRS0lABRRSigBKKKKAFpRSUtABU0EDzyBUUkmmxRtLIqIMsxwBXrXg3w0bBbdmgQ3jfO6SxZIGRgcqRQAvhbwzbafawkuTfOyuQ8RyoPQDKGvQtE8IHxHrMUEBmjtYQVlmGFB9QAFGD9PStDQPDdzq15FZSKiT5Es8wwrou702+gH517XbQaf4f0eR2eO1sbWMyTSuQAoHJYmgDOu7nRPAXhGe/v2+zaXYoC5HLyMeAoz1YniviX4o+O9Q+IHieXVL/MVsmY7S1DErBFngf7x6k9zW58b/ibP8QtfC2nmwaBZkraW7H757ysP7x9Ow/GvNDQA00GiigA70UUUAFLRS0AFLSUtABRRRQAU9FLMFUEk9qbitbRoo1ctJG0j46DsPy60AeifAxZ4L2+aGNdsiYaUgbuOgBIJ6mvbbG9iiRZluY0XGw72VQfccjmvnvw7ct4b1uC4t3RYbjnY3B256Hkc16vp2vWEsf8Ao5NxMH+becbyeePn9KAOy+0wXcnnLMiyqu0y7uvPb5utWYbiBHZUd3B5JVCxz27YrjNR1Zf7MYWiTNOEBCRqTt575zx1rmhfagk0YknnzMwJVR/qweVz8nzcdvegD2yN2lAMJ344IdcA5/4DXN+Jp7uCKR43RCxO3YQpHsOlSeEzuj/cXCbAo3E4yW/Tj0rprizhvITEzqW9dwGM/jQBm+HJzNoduzFvNRcHew4J9ea0LKedXEMnBVuudwIPTpVC4trjTbZ0tJDNEMlg5yR3znPNTeHLm3nQOr+Y4J/g6fpQBr+K7e3vPBPiC1u0QQSadOGLjcFOwkHHPQ4NfAQ+6PpX2z8WdYtdH+GPidy4Es1s1tGj9C0hC8cc4BJ/CviboKAEpKU0lABR3oooAPrXoXw88ZSWFqdGuihgkYeW7bsrzyMhhivPaOaAPcbnUmn1NYNO2/aMfK4Td5nt0Oe/PripLe0CzyW8lhL9rkXLkxDGeR/d4xXnnhTVFleGKWRYZ4iNshwS35qf1r3OXT5rWz864uJN8iKyrF98A4+UHjj2oA8V8Z+EpbNJLy1DyQg85ABA9fzrhXUoxVhgjsa+m0hhs5n+0XsIWWIgiU7uPfD43V5R468HiMi+0eQ3VoybiwUgg+je9AHnNFKwIOCMUlABRRRQAUUCigBT2pabUkKGSRVXksQKAOx8A6RJLdx3ckGVBHlswP0yODXpCSSRwXMU7NMg+Rg45J7EZTtWX4dsoNMtoftZREIUAjkhj1XO3FdH4KvW174g6XpojkniedmzLj5UUEknAHOQKAPePhtoK6ToELtFGt1dKJZNowFB5C/Qc186ftG/Fb/hI75/DHhy6zoNq/8ApE0eR9rlHUZ7ovQep554r0T9pb4mHw3pJ8LaFKU1a/izczIcG2gPGB6Mwz9B+FfI3QYHSgBDSUtFADaKWkoAKWigUALRRQKAFooooAWiinAZoAmslQ3CeapZc9PWuw0TQpGuRKWUR4yuGBJHPAGfaub0Oyn1DUIra0QNM5woJAyfqa+qvh54Jt9PsYfNjyVAZkLE/N6/ex+VAHlF74Jv9Wiint0dGEYI3ccAeu7qat2unXtjajzI2Elq4CHLNlgPQkg9/wA6+iDYxrkKuPxNYeu+GYby0kVoI3OMg7eS3bkg8980AeZ6PcxzqZLor9tmQxuHXBA54xtrcsrC2tZ0S2aCZ3GHd0Hyj2PGK4/X/D2r6JqU080SPA+MPsVVjB9cgevWtjQLgC6FvLeiSdIz5YXGB9CG5I6e1AHeabcLZgpctCsTngINrH/x7/JrpbWWKViEyrryA2cgfnXAX1peyRKpleMcBXGXJPrjccD/AOtWt4dnvoJHivNrSnkSgHkfTHX8aANvXAIrWeURrIxT5gxwoHr901keCjEbZSiR5XOCFHGffAz9fat2+ZJ7GSFlR3KEeYw46fSuF+H+tt/ZFys01tGbeV1ViAoVQT15HGB+lAHH/tQ668dlpOhRSgidjeTKo6gZVc/jn8q+eDXYfFTxU/jDxneaj5m+1TEFrxjES9DjPckn8a4+gBDRRQKACkpaQ0AFFFFADo3aNwynDCvrX4DeJ08Z+D5tNuZAmqaZhSF4LRHow56dq+Sa7f4O+Mn8EeO7DU2Y/YJD9nvEB4aFjyfw4P4UAfQfjfSbrw9G9xDGt1ZXEgzvLFgeOnUCsHTp49Qs9slhEwJGQV3J/wAC+TuK98v9NstQtXguES8srhQyZwysOoI/A8GvEvFml3Hh+5nthbLbWygNE0ag+YpPQDbjNAHhnxH8JPod4JoUb7PJls8Yz7cDiuGNe1a/JaXluou555k37FVgPmzntuAHIryjxDpcuk6lJbypt/iTpgqenc/zoAzKKWj1oAQdKKB0ooAStnwsqjVY5pELJD85wuf6Vj1r2M6W2nMjqC8h3A9CB+VAHV3OuNeveRgRxIG3gKAo69eleh/A3Vbfw4niXxXq02bXT7QRRgkAvIzcKBnqePzrxK0BL+e7ALz8pNOvtXvDpZ0sXUhs3l854w52lh0yM4yKAGeKddvfE3iC+1jU5DJdXchduchR2UewGABWUaDRQAUlFFABRRRQAUUUtABS0lL3oAKWilFACgZIAHJ9K7XR/hl4u1GwS+h0adLRhuDzEISPXBOcV6T+z34B82ODxDqMUL/aGzaq/JVVP3sdMk/yr6V3HuCe2BQB8weA/h/d6Pr1lc6vbzR2pBO/eEKtg46NzX0VYshSNUYkDjdjk0upRrcxYfkKc4zjNLEikbmHQcd6AH5GWKknPWqk8yicgEeYRwpxirEkKBTnC55rGvfKjkU5UkHhjjK/qKAKviLTLbU7SQOkkoIwYhJgP2weRxXk91o2q6LqaXOlRoHVivkJOXAwO/zden6V7PbDcQqoTk5LE/0BrmfFVrdWN/HdQbHgGXfKE5xz17HgD8aAMzwz4wg1KJrPWoJLKdQMnYzg9Ofu8da1LrTnhug9lOx3sCWCqDjHUHZ9KoXsNv4p0oeUiwPJlXAj+Yj6leucVw+rNr3hIeVHc+YiquXcqSi8jqT70Aev2d1BGJYroomE5Z2C7ieo6ivmn4geLLe0Gp6H4XuJTZXE264mLk5x/CpDEYrC8U+K9V1dvKnvJZIkyB87Y/meK5I9aAG0lLRQAlJS0lABQaKKAE9aKXrRQAUvtTaWgD7O/Zn8af8ACT+BE0q7fdqWiBYDx9+D/lmfwAK/gPWu58daUL7R3mSJGmtwXUsccd+9fHHwQ8ZP4K+IFjeO3+gXRFpeKTx5bkfN/wABOD+FfeGwOWjfBVgQfQigD5O8VTedG4sLy3jt8iUBWy4I4bb83XmuE8WWQ1bThcxeZNPBHln2kAj0HX09a29Wup9G8X6pZ31qrJDcSL5cuehYlWHPpisrHkXbRXU8q286HYE5DKeo+7QB5pS1c1e0NjqM9uysuxsAMOcVSoAUUUUUAJ9asBnlQA8qvAz2qt1rT0iMzzwwx5MjOAoB5JPQUATFWjgVDtXjJ56/rWXIcuT2zXd+MfBuraLpS6jeIoi3+U2D8wPuM1wRoAKTtQaKACkooFABS0n0paAClUZzyPxNJS0AFLRRQAtKehx6UlOFAH2H8H4fK8G+H/skyvbQ2as/P3ZGwWHX616Vu3qMEnNeD/st+KI5NC1Pw9eTssltKLi3LHgRsPmA+jc/jXt6zosm7cSvXIz0oAsTAhT8uSRyMdaw9N1G2edbUOTM+WGQRjBPHIFdIqiZMHBUjn6V8xzfEB7D4m3JmlYaXFKYgUcKpUE/N2z1/GgD6C1d9gj+ZVJPQjk1jrGFkIZA5ZuzdOO/PSo9J8RxaxafaYbiEwp0k3jv9GqZryAz4Z2UsD8xGQ2Oo9qANu3YpH8yhe2Ov41S1e0ivYJYJYtyuCSD0P04oe6AgiIZWQ8gFf8A61V1v5JIwbeEhzglTjIGOlAHE3rf2JqMvmSxR2uxV2nam0jjI6dD+tZWvaFceIdPS3mug6sGaOZSWLD0J3n16V02r6O93qTXUtuwjTlstgHr1+YZrqtHtYoLX5ogkOBhFJIX9TQB87S/DK50+yv5bi0efy0JXaecbT83514uM45r71nexv5orDyBJGy/PwRx0HbmvhrxDarY6/qloqlVgupYlB6gByBQBnV2Xhv4fanr3gnW/E8c9ra2Gm4AN1IIxcH+JUJ4yBj6k461xteja78TDqHwk0XwPbaYkEdp81xdM5JlIcsu0DAA+bnOelAHnFJS0UAFFFFAB3pKWkoAKKKWgA6+1fd3wM8XReL/AId6XM0/malZRi0vVJ+YOgwGP+8uDn618Iivav2U/ETaX8Q30qRyLfVICm3PHmLyp/LI/GgCx8fney+KeryGAtGNj4K8MpUY6jp1rl0xf6WZrKKNyH3ZVQSpxnGdo9x+FdP+1RGE+Jsn7xiz2ULYI4Xg9OK8v8O642jXaqADGWyzdxQBn+IZTPqbyN95lUsPfFZvauk8dWyxax9ogKNbXKh42QYB9epNc2elABRR2ooAaOtej/Abw8viL4iafbzoHtoczygtj5V/+vivORXvH7J6wf8ACW6izZNx9mwmOwzzmgD1/wCNOiW0vwy8SzMhzbW/mR5Y8EMOfc18Vdq/QDx9pZ1rwF4i0yORY3uLCUK7dAQu4Z/Kvz/HKigBDR2oNJQAUtJRQAtFJRQAp60optKKAHUUUUAKKfGjyuscKO8rnaqICWYnoAO9MrU8M6zceHvEOnaxZBGuLKdZkVxkNg9D9RxQB9XeCPAVn4bsbISabDYXd9aJFcKWLt5pHzfMRweeR0q9o/hvW/DOuD7Vqs+p6E6HMc3ztERgADjp+Nczb/HvQ9SY2lzZT/N+9ilznYeoUrt6j1Br0DTviLoNz4eGqS3ltb2y5DtcSLGePRWwx/AUAR+IjLqui3UGi3k9kUQlpIo9zfTFeB/ER9Cg8K2yRWs8urofLluGRgqtgd84z1x171D40+M2tSeK7q58N6giWAISNEh2xuqnIJB5rh/Fnj7xJ4st47fXNRM1rG5dYY41iTd6kKBux2zmgBmj+J9QsLc2sF3JBA7ZYhjXoXhL4g2tqEtvEl/5tp5RCy2yb5M9gfl5PrXjFPVip4oA9wi+JmnaYlwNBt5pZGJMdxcnhR1wU2jrV+3+MWp+RHcJYW8buxV1LEL04K/NkDrXgsExRx87Kp6la9Q8A/DifxXaG7stetZgm5Tb5ctkc4PpnNAHtHgnxANctc6jdrcSSD5o1LAgdume1aya7YxRCBpWdZASrCMkLjtnHpWRovw/Gl2VjbRWIEmd00xbv/3z0reHhTytQjkiaCNcneFQAY9MY/WgDzLwbq2sXPj+Wx823FgWb92yBSVBGCOnJ65ryn466aNM+KGsKiFIrgpcID33KMkfiDX0bc+FYLTxDZala280zxODI8Z2lgPfIrwb9oyeWbx/GJYmjCWaBA3cFmPqe5NAHllBopCecd6ACiiigAopM0tABSUGjpQAUUUd6AFrovh5fyaZ460G8hkWJ47yP526AE4OfwNc7VnTJTb6lZzAZ8qZHx9GBoA9o/ahuorjx/HLDPFJ/ocaNsAO0jPBIrw9uvWu78W6nceIPEs0xgiUzgBVV/l6depxXDTIUkZT1UkUAaFtqBlsfsF4xeANmJmPMTe3tVe3t4nkeGeQRSfwt1Un8qqqM0rigB1xBJbSmOVdrD9feinNOZYwkvzFfuueo9vpRQBXFe7/ALMCx2viP7S87K1wjQonZzjPPFeVPYWkkiBRKASRubHHpnArvfAU0vhnVLGeJrOVVlWX96rgEZAIGFyOv6UAfXyxJc7refJjmBicdPlYYP6Gvzy12zTT9c1Kyj3eXbXUsC7+uFcgZ9+K/QZXyQVPXkHNfHn7SWitpPxUv7kCMQ6pGl7GEXAXI2sD77lJ/GgDy00lKaSgAooooAKKKKAClFJS0AOFFJS0ALSnrxTaWgBwOMEUrMXOX+Yj15poOOlOD/IF2Jn+9zn+dABmlptWtNnt7a9hlvLVbu3VgXhLFdy9xkc0AV+OmRmlFfUFt8N/DHijwck/hTS7aGK5hLxzygs4kPvvzwcjFcYnw48NQXi6Zq92qaygKvb2zsoZscYyTk96APExX0H+z14baGxlvr+4t4BdH93AzYldR1b2HNYun/CzRJr2ctc6q1tHL5ezbh09CTt579K9D8NfC3QoriG+0XVb9ZLfICzEEqfX7oxQB65aCGzgCG4MgXnD4yPyFM1HU7SxtjcXJAjBwW4wPc81g2elX8LEy3Xnkt9/ocemBxVLWvD1xe27rNqUttAsgdQucjnJzzg0Ab2l+INPu3AilUE5wuev6+lfJX7QmsDWPiXdGOUSw2sEVvG4GMgDcf1Y17o/h6QW8qafMv2qQbYbggD6/KQSTjj05r5q+J2izeHvG+o6bcNukhEZLYAzuQMO3vQBy1a6eILuPwjL4dWK2+xS3gvmk8oebvCbQN393visikoASjtQaKACiiigBR1pP5UlFABSikpaAF71Y06Fri/toUBLySBVA6kk8VWFepfs4eGY/EfxOtDcrutNOia9kHYlSAoP/AmH5UAddqHwzn0PSo57q2LtEgFy+TiNT6deRXhusIseozon3QxAOc5r73+IlpFP4J1pp/NbbbOwCYzkDjGQa+BtUVUvJQilVBOAetAFQHBFKdxXODt9aaakS4lSF4lciJ+WXsaAGUUDmigD0Fv3kjxLb2bKGBLRq24jv1HauitxBNHM67Y4ok3K4AMkZBHbA781jE/Z9RLR2/mbsbzLEGJXHUcc81atW1CKJo2tppISfvmPehz2IBGKAPpP4Za9H4g8J20oaRp7bEE4kADEjocZ7jmuB/at0YXvgnTdYVR5unXflM23J2SjpnsAyj865r4X6zN4d8ZpJc3UMlnep5E8abgIznhgCcZzgZ9DXvninQoPEvhrU9FuiPKvoGiD9drfwuPo2DQB+fxpKs6hZ3GnX1xZXkZiureRopUbqrKcEVWoADSUUUAFLSUUALSjrSdqUUALRRRQAtKKSigBe1LSUtAC1v8AgXw8/ivxbpmipKsP2qTDyEfdQDLH64BrAFe3fss+Gjqfi2+1yVitvpUQRQP45ZMgfgAGNAH0D4T0m80m2Gn25SOwt8Rxhs/dA/h54qnqXwv8Malqc2pXFtP/AGhI/mGdZmBDeuOn4V2oGCB074pex9KAPHfie8vge0ttQWOKWweURu+AHJPY8dTyeKT4a+O9K13XZbG1d7ZQnmxeaQDMe469vx4r0/xNodn4m8PX+jaioa3uoygbHMb/AMLj0IOK+MLca14C8Um4uYH87TbloJByE3DjAPuOnrQB9eXF1cxXLCQYjJ+TYc4+vtT2vXecxhA5C5OQcfyrkfBXxK8O+JYY45L0JfMoH2VlO8kjoMDt061d8RXtlHMqTXDW8ZIxIjBd3PTt9PxoA6+0srWSYzmFDKfmyFHBPcV8a/HS9S/+LXiOaIkxiZIhkg/cjVe30r1r4h/GGz0K3bTvDLi6vNm0y7iUhPpkHqK+a5HaSRnkYu7sWZmOSxPUmgBhoopDQAUlFFABRRQaACiikoAWj60UUAOHWvrT9lHwydL8G3eu3VvsutVm2wu3VrdOmB6F931wK+ZfBXh248V+KtM0K0kWKa+l8vzH6IMZYnHoAa+/tOsrXTNPtrDToFgsraMRQxLwEUdBQBh/FTUotK+H2s3ExIBhMYwATlhivge5O6U/MW56nvX2l8Z4zrVlb6ClzHBFJ+8mkYjggfKOo615Fa+EvD+mQxNEy3FwXKnenOe4wW4oA8LgtbidwsMEkjHoFXOafcWVxAgeaCREJ25ZTjPpXscbmC+lQYguFkMRSJCQo6Z5zzVbUvs09uunvBe3chkL7lBO5vXBWgDxzpRXoHizwxbrZpdaSGj5IMbDG49wOBRQBr3baXeS28GlXSNNINu7y/LBPpt9Me9dj/ZU1paWE0U7LDNIquruygsuenzDjrXKfEvwZ/wgevLJAlx/Zlw2bS7AyI/VHOeGHr6VRl1ZZ7eOYa9qLoBtMRfIRs9cb+R/OgDvNW0u3W3e2ikleWR28nZ3YDkZ5H61618Mdbm1fQ/st3Gy3tgFic8/OuOG5A+lfM13rd4bLyl1cyxK2QrwEqxz17+xzTtG8a6po+rxX9lPYyXsABG+BlEi9Cp6cYoA6v8Aam8HtZ61beKbSIC2vsQXe1fuzKPlY/7y/qvvXgpr7ZgvtJ+Lnw3vYbbETXERjngZvmt5hyD9MgEH0r401zS7vRNVutO1GIxXVu5jdT7dx7UAUKKKUUAJS0Cg0AFKKSlFAC0UUCgBaKKWgApRSUooAcOASe3Wvsj9nrwq3hX4fwy3yPFqWsuLqWOTgooyI1A/3DuP+9Xzz8CfCNn4x8fRWeqhn0+zga9niA4mCMoEZPYEsM+1faC4UkAAeigYCjGMD2oAfkdOmadkHtTOnXinZBHHPrg5oAXcM9Mn6V5Z8cfCMWtaTLc29uhurvyrd5WkKhGBPluRg55JB6V6iDk8/nSSxRzxtHPGskTDlW5B+ooA/PKRZrS6ZH3RXELlT2KsDg09tTvihQ3cxU9Rur0L9oXwunhn4kXZtYvL0/UkF7bgD5Rnh1B9mB/OvMTQAhNJQetJQAUhpaQ0AJSUppKADtRRRQAUd6KKAFpRSCu9+DHgeTxv4xgt5ombSbUie+foNgPCZ9WPH0ye1AHuH7L/AIEbRtFk8U6lGVvtTjMdojD/AFdvkfP7FiP++R717Zd3UFlaS3N3IscMQ3MzMBUoAGAAFUAAAcAADj8Mfyrx74ra/qerXR0fRreP7HEw82WRsb29sHleaAMnXfFF1qesi8W9igiVysQVSytkfLnBPtzWRbaxcziYFYtxHLspLMenAI4z04rLsjqFqsaWtpF9qIYsUdiIgvqADzyOKzftFrLCpuZG35bJ8ogqcn/ZoA0PEMWoC1S5uJLCN2xvGw5JPQZK9RXPvd3stxGk12BOiFflQAr6Hpk8VqWsESWipf6dcXEc77Y+AdvYZ+Ufga5XX4FstTiAR1hkYH53GQOmMg0AdM8dpLbqs0hnW2wPLGELH17HPSisCSRrucGS5EFmGCRzRk5b2zu68UUAepWfxQs7jU30Hxvp7XFncqqF/JjZEJ4+f5sbe+az/G/wd0jSwmraFLONKlxuEeZTDn7rg4OUPf0HNeJXmrSXch3x2z7OEdPk4z0Az0r3H9n/AMa2pZvBurgiK8V3tGeQMuWHzQ9O/JGfTHegDyK+sEhndEuTHsJyJLd/mA4xwnfrWHNZoh8wTq0RY8jcCPzxXT+PNF1LwJ4qmsLt7kKkjNaXLLgTw54Ye/YisG51eZ5JRBdSMjjkF9nJ6nrQBP4W8Wal4R1uHUtGu5AVYGaETMEnX0cZ5H1r1vxtDo/xd0aHXdKmjtNeSPbLavKCSR2Ixkd8HvXh8zEAMJCxC54YEH1FVrO9uLC7S5spWilRgwx0yPUdDQA2/sp9Punt7qMxyIcEEYz9Kr17V8P73SPiHN/YniOGFLgjMMgwshPouAM03xp8BNc09Xu/C7rq9kBkw5Czr6gL0YD8/agDxeip760uLC7ltb2CW3uYm2yRSqVdT6EHpUFABSikpRQAtFFLQAUopKXp3oABVvS7C71TULex022lur24cJFBCu53Y9gK7X4efCnxH41eGe2g+w6QzlX1C5GE4OGCL1dhzwO46ivp74a/DjRfAFq5sN93qcqlZtQnUCRlP8KD+BOmRk5I5NAFT4MeAD4B8OSxXrQzazeuJbp41BEYAwsStjJA6n3PtXoOTimruL/KBj1zzTl6570AcN4j8YoPET6LZPmOGLdcyo2MMcYVTn0znpUGnyy2u3ULaS42q/zJKxAYHjuOeKyvjLeQeB9PTX7KxWae+uvKk3KSiNs4bgcDjp614o/xM1XVmt7JLI3F1M6wrHEQPNYnAAXb1PT8aAPr20ukuoQ8ZHuD29qmDjzNoPzAZxWP4W0j+xdIitmkeW5cB5nY9Wx0HsOnHpWhqLxxWMs0032dI1z52cbT2/PpjvQByHxg8AxfEHwutpG6Q6tZFpbGZzhdxHMbeitgc9iB718X67pN/oeq3OmavayWl/bNslhk6qf5EHsRX6BWc4uLaGZHV1ZQQ6fdb8K4b4vfDSx+IWlo6NHaa/bJttbxhhXXOfLl7leuD1UnPTIoA+JTSVp+ItE1Hw7q9xpmtWklpfQMVeOQdfdT0ZTjgjg1m0AJTTTqaaAA0lKaSgBwC7GJb5sgAevrTaKQ0ALRSVPaW0lzKI4tuScZYgAfnQBu+A/CWpeNPEEOl6UgDH55pmxsgjzy59fp1Nfa3gLwtp/hHQYdK0pHWCH70smN0zn7ztj1/QcVwnwa0aDwV4La41l7PTbZz5lxcTuqFyfuksTwOmB71zPxM+Nwu3Gl+DCwtBkXV60ZDMo7R4PA65POc0AeleNvE4n8/SdKuJY3HE9xEuQAOCoIOfrXmd1YhhDK97mG4AL+e5Mfp0xwTXj6+I5VnkMLXTrnEe5vlC91xirN34nu5XdjBEisgUK6jb0PIG3/AOvQB63a6dCs0gW0tkf7scgGSxz2JXt71HdWtxFdGS8FpMERvMwEUjjAI+UEivDp9ceSQSG5l44EakKD69KhOoT3k/lr9umkdgAquzs3YKBQB7NoFvaavPZ6bZ6yjajes6JAjEMAATu4OMDH4jNd7pXwathAF13Wbm+jcFpLdRtQMeuGznFWPg/4A0/wZoUesaxbwwa3cpmWad/+PVT0jDE49yeOuK9DsdW06/d0sdQtbhkbayxSqxB9ODQB4h8Q9HvPCMsdrpGhTXembPNjmiiLxxgdd5zkMPT0or2bxs0sPgvXkTeJprCeKJQD8ztGQvGPUiigD4CADShS+Mnk4OBT45XtbiOa3mImiYOki8FWByCKrs5aXcMg+xP9akZ5CQxySOeeaAPoHQPiF4Y+JGiQeG/igiWd7GB9m1cMqLuxyxbgRngeoPeuG8bfCLxDokL6jom3xD4cdfMi1GwIkBXOOVUk5HcjI9681YuR82K6Lwh468TeD2kPhvWLiyWQYeMBZEP/AAFgR+lAHOEkcHPHUU3vXp9/4/8ADPiaFD4v8GwnUiQ0upaXL9nkmPQsyAbSe9QXGlfCu5dvsnibxJYA42/adNSYL9drjNAHnlpczWdzFc2krwXETB45I22srDoQa+lfhn8aotViSy8RyfZL5AAbjzMJN26HkHua8x034SXWv+WfCPibw5rAkDMsH2ryLkAdd0LjcP1rkvF3g/XvB93HB4h06azaUExSHmOTHXa44P060AfWfjG08HeM7Up4js47hQnyalbsFkiHs4GfwII9q8R1r4G300Mt54G1iy8Q2wbK24YRTohPGd2FJHfBH0rkvB3jWDSreSy1vTBqNlJjBSTy3j/Had3419DeCbLwT4sls9R0BLZNRt4twEVxieIkYO5AQSR64oA+VNb0TVNCvXtNYsLmzuEOCk0ZH5HoR7is7I9R+dfoTaW80FoLaa6nulXqbjBJ/SsuPwh4djumuU8O6Oszc+Z9jTJPrjGKAPhKxtLm/uBBYW891OQSI4Iy7EDrwBmut0P4X+NdbtftOn+Hro2+/ZvmKw8+uHIJHuBivtW2s7a03yWlra2pI+eSCFIyR7lQOK53xR4+8J+HQn9t65AWfICwHz347EKSR+NAHi2h/s4ahJcSDXtetLeHy8xmxjaZi/GQQ20ADnkE16z4T+E3g/w28c1rpQvLpRH+/v8A98wdTkOoIwhJ54rlLn9onwlBM8dvpmtXCLwJkEag+4DHP51nat+0ppUZU6N4avJyQd32ydYsHtjaGzQB705Ync3X6da5LVfEbvfXGm6PcWs1+mMxtgqmDyGOQQcdq8y+CfxJm8RJrUHjDxVbWd9JMssH2gpbrsK4KxtkKuCB8v41X1bxXonwp1G6fSdQfxPeXrtOF+2JJFGx6l2Uk5NAHpLWuu/Y5r/xFqVnYWMcpka4MuxIlz8oLMwX2rJb43eB7O6is5NVurrHyveLbsUUjueMn6gGvmTxx488QeNb559bvXNvn93ZxMywRDPAVcnP1OTXLg0AfoFeWuk+KvDpguUt9U0TUYVcYJ2SoeVYHggg4I6EGuV8FfCbwv4Q1x9V0yC5mvuRA13L5gtweDs4HPuckdq8L/Z1+Ik3h7xBB4c1SctoWpSiOPzG4tZ2OFZST8qsThvwPavpfxx4iTwh4Q1fXp7d5hZRjZGvVnZgq59gzAn2FAGD8Rvid4f8BKIb1zfas4yun2zjeo/vSH+DrkA8nt61wHh34u6P47nttK8QWx0y7aUGHD/uZWyNqk8kH68cV816nqF3qmo3N/qVw9ze3Mhlmmc5Z2JyTVQ88daAPvfS7fVNPcJdvB9nX5V2gAsCeOAMCreqeINM0l7candR2kczFFnnZUiVh/Czk8E9vWvk/wABfGrxB4bgh07VGGsaKrcxT8zRLjGI5OwHocj6V7j4V8T6b4v0mW8l1LTU0eQMk9lfyKHK8g7gX446HFAHc+MPC+h+LdOjsvEtgt3ArK8TqSskfpsccgEHp0NfNfj/AOAOuaIk974Yn/tzTo1DeUqbbsZbG0RjO/Awcr154FX/AAv8af8AhEPFd1o/2qfW/A8M7RWksif6RBFngoTgsM9mzwOMV9GeGvEGj+J4JJ/DWpwalFGcO0G4FCfUMARQB8A39nc6feS2l/bzWt3EdskMyFHQ+hU8iq5FfoF4o8L6N4ktZLXxFpNreK4ALyRhZhjpiQYcY9jXl3iT9nrwpf4fRbu+0ZgMFc/aUPvhiGH50AfJtJXv17+zXqq7vsPiTTp/QTQvEf03VkTfs8eK0eQLfaRIirlWWVssfTBWgDxilRdxxkAepOBXrl98EtasLS3uGU3TOBvgU7WU9+fb9afrngqLw7YRandLZpbRAHyUnDSFuOCC2ex6UAea6ZY2syss7ytOeY441yWGOvWuo8Pax4d8MpJcNp1zqOoYBhMx2JGwzzgHntXKSa1eLI7W1xLEW43L8rAegI5ArOd3kbdKzuT1LHJNAHW+L/HOteMLkNqUh+zociGMkIO3TJzWHtnCZ24XPUDpnt0qgmQO5HXGakVpE5XAz7igDUtbdnCDAweuW249ulaz6dpqNM1xewkH+EkKy/4muVjbEoIQHngE1p263l/dwRWlp9pndjsgXLtJ7BQc0AdPZ2Ph6d1MmoLbNuCgCPcGHGSRv+te7fAvQNEtbC+8QWqu0EcjLHd3CYwq/eZeTgDGM1xfgL4S63qciar43ji0TQrZS8kTkLLKoGcHnCqfXr6VH8Xfi1a3Gnv4X8DxLFoaIIprlEK+cv8AcjB5C+pIBJHpQBJ4m+I51TVrm8b7QYQXjtgeY1T/AHe5OM81y+r+PtQDtFYSQaepUMSsI+cgDOTtzn3rziS6kkcAeZ8oxyxx9cYqAzOS277zfKQOP0xQB6Zo3xA1ZbGKzn1m4eBQQySoHYA9SGIyfzorz2OcxyCSICFwoAxyMY5ooAx9xznPNLu+lMpaAFzS9SOQKZS0ASMoUDDg57ClCH2/MVFQKAL2l3t3peoQ32m3MtrdwPujmibayn2NfZPgXxFD8QfhlFe6pZ22p3G1oL+0aMFHlXsBjgkbW46Z4r4ozXofw1+K2seAdMvrDTbOxuoLqQTf6SrEo+NuRgjtigD2a9+FHgPxPZpPp9pqXh2c9Vwy8+hWTI/LFeX+OfhpqngF01HS7+/ubXOEv7QLH5Z7Btr5HHfpXRaf8dtcu0jF1/ZMbO+1j5bErxxwTjHvWL4y1/UfFcEcF/q0n2cNvWGxg/du2eh2nnj1oAg034v+OrFYkOvrcxIBxNZJIQB77c1Yu/ir4pv7zz4dfube5Zz/AKLbuI4SvbqMZrljoVtdKboXGIMNtV4mUgj++cUy20iJ3k+xpaK8XDvI5BJ65UE/QUAdVceOPFWpQOX8WursNhicY49ciuH1+/MzMv2m2vWc7ndUYEnPXnoauG6ZSq3jGOLn5iBvOeOfm6ev41BqMzSzgQSLKhTaGYeYGI9OOvFAHMvjdjBX2JrSaB1hSWIBgACBuB/GprmwYyI7x4GM5MZUHHU9BT7kXKKI2lR0f5sxkD8ODQBj5cv1GSc9qX95uI5OfUUSDacnkDsDSLGS4HKg9CwoAZwTywHvSiMkZGCB15FEyqkhAcNg4zimq2D/AI0AIcjocEdCK+zfG15P44/Z2vdQsoCJ7zTI7t4UcnaYmBkAPf7jHHevjJiCeAcV9j/s125uPg3ZQ3AZree5uojjsjNgj9TQB8c9fxp2AFzWp4i0tdD8SappMzufsVzJAGUAkhWOD+VZtxIHKbR7n3P50AMYEjceM1JHGHH+tUZ4AJPNRkZ71LEpMZxLGgHPK9/yoAfFAZpNkJRmB6bgP50k6LbswwVk5GY3yCfwqe18u3QHfE7Z56gio3eAs0ixqB1wCf8AGgD0T4cfFfxP4fgWyXUGvLCHlLW6G5QPQNnd+te1xfG7SrbTbe612zaBpCQ62uZNpH1NfL9jOttDlIppACfMEWRj0yeaqNPIwcMARwQWXgY69qAPrWL45/D+aRY2vb6Itg7nsztHHfBq2PiP4Au7T7bb+IoI/VXBSQY9UPPavjJ23AdBz6CreiaNqGuajHY6RZyXt3J92OIZPvn0HvQB9I+OfjToP9ktH4avYryd0P8ArbaVADj6jBr588ReJNV8QMPt048vOdiudv6k1754d+AVhbaFBJrN251RlzKqMBGuf4R6kUmrfAFLmNX0a6hAPLNONwPbsPSgD5naNlIz+GKs6Vpd9q98llpdpPeXT/dihQu3147e9fTXhz9nrTLabf4h1KS8OQVitU8lcehzkn8KpePfiboXw2NxoHw50azttUHFzdGEqIjg8DOCzdCDkr7UAcTpHwL1OC2W78barpnhq2c4SO5mUyycdBggZ/E/StdfCXwis3SC41+7vJlO2R1l2AH1GOK8l1jxbrmvXb3Ws6hLfTMQxaUjaCOh2jA/Ss8TyNKTmLK8/exmgD3tvD3wW04vcfb7q9KLu+zJMzFhjPp/Wnw/FnwZ4URF8D+C2F0pwJrwBBt6nDqzN+FeE2t7KqSrFKsZdcs27bg/1Bp7y4gQ/IApzjcDlvXp04oA6Txn8RfFPjLCaxqUxtSCBbWqeXERnO1lXh8cdcmuTZXaMPIXY9ASOg9OlTfaYzPG77VUHLbU6nv2plxcweWoTBOScgEfgRQBCnlic5Xp09vc1GPmkPlgBegzS/aVZduwAbcZ6k/rTJZULYDPsHQdP60AWMmNlXeFbOGGf/r0VB9twr7VJduA7N0FFAFGloooAKKKKACgUUUAFOHSiigCSHpJ/u1uWn/HtH9X/kKKKANbTPu3H+8P5Gq93/x9y/Rf5UUUAVJ/uS/9chTIf9Za/QfzoooA0Lr7p/3h/OqN5/x9n/e/woooAo6j9/8A4DTE6v8AT+lFFAFF/vGhPvr9aKKAHH+te+fs1/8AIG1j/rof/QaKKAPKPHv/ACOWrf8AXy38650/eH1oooAReo+tPX+P/coooA24f+PJfoa1P+YbL/10T+RoooAx5f8AVS/7n9azD/x6T/79FFAFPsPpXs37Lf8AyUWT/ryk/pRRQB3v7TP/ACB7H/rsf5VxnwR/4/f+3f8Aq1FFAH0L4D/5Fi1/35P/AEI18v8Axm/5KLrP/XUf+g0UUAeYXX35Pqf51XHQ0UUANboKQdRRRQBOf9UlRr1NFFAB3FNoooAX1ooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows a large retrosternal mass with inhomogeneous enhancement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_47_23295=[""].join("\n");
var outline_f22_47_23295=null;
